Pharmacokinetics and Pharmacodynamics of Cannabin

Clinical Pharmacokinetics 42, 327-360

DOI: 10.2165/00003088-200342040-00003

Citation Report

#	Article	IF	CITATIONS
1	Hybrids of chemical derivatives of Escherichia coli alkaline phosphatase. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1975, 412, 262-272.	1.7	9
2	Cannabinoids: potential anticancer agents. Nature Reviews Cancer, 2003, 3, 745-755.	12.8	616
4	Relationship of Â9-Tetrahydrocannabinol Concentrations in Oral Fluid and Plasma after Controlled Administration of Smoked Cannabis. Journal of Analytical Toxicology, 2004, 28, 394-399.	1.7	194
5	Cannabinoids in pain and inflammation. Inflammopharmacology, 2004, 12, 99-114.	1.9	32
6	In vitro/in vivo correlation studies for transdermal î"8-THC development. Journal of Pharmaceutical Sciences, 2004, 93, 1154-1164.	1.6	35
7	Cannabinoids courting attention because of their potential in CNS disorders. Drugs and Therapy Perspectives, 2004, 20, 19-22.	0.3	O
8	Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students. Human and Experimental Toxicology, 2004, 23, 149-156.	1.1	57
9	The Cannabinoid System-A Brief Review. Journal of Industrial Hemp: Production, Processing and Products, 2004, 9, 87-92.	0.1	3
11	Cannabinoids for Therapeutic Use. American Journal of Drug Delivery, 2004, 2, 229-240.	0.6	13
12	Effect of Acute Marijuana on Cardiovascular Function and Central Nervous System Pharmacokinetics of [150]Water: Effect in Occasional and Chronic Users. Journal of Clinical Pharmacology, 2004, 44, 751-766.	1.0	27
13	Hypothesis: cannabinoid therapy for the treatment of gliomas?. Neuropharmacology, 2004, 47, 315-323.	2.0	70
14	Randomized, Double-Blind, Placebo-Controlled Study About the Effects of Cannabidiol (CBD) on the Pharmacokinetics of ??9-Tetrahydrocannabinol (THC) After Oral Application of THC Verses Standardized Cannabis Extract. Therapeutic Drug Monitoring, 2005, 27, 799-810.	1.0	152
15	Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood, 2005, 105, 1214-1221.	0.6	67
16	Drug use and the severity of a traffic accident. Accident Analysis and Prevention, 2005, 37, 427-433.	3.0	55
17	Spray freeze drying to produce a stable î"9-tetrahydrocannabinol containing inulin-based solid dispersion powder suitable for inhalation. European Journal of Pharmaceutical Sciences, 2005, 26, 231-240.	1.9	55
18	Effects of cannabinoids on nitric oxide production by chondrocytes and proteoglycan degradation in cartilage. Biochemical Pharmacology, 2005, 69, 635-640.	2.0	28
19	Altered Cytochrome P450 Metabolism of Calcineurin Inhibitors: Case Report and Review of the Literature. Pharmacotherapy, 2005, 25, 1021-1029.	1.2	9
20	The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. Psychopharmacology, 2005, 177, 264-271.	1.5	41

#	Article	IF	CITATIONS
22	Harm reduction—the cannabis paradox. Harm Reduction Journal, 2005, 2, 17.	1.3	15
23	Cannabis and tobacco smoke are not equally carcinogenic. Harm Reduction Journal, 2005, 2, 21.	1.3	43
24	Pharmacokinetics of Cannabinoids. Pain Research and Management, 2005, 10, 15A-22A.	0.7	156
25	Addiction and Pain Medicine. Pain Research and Management, 2005, 10, 38A-43A.	0.7	14
26	Patterns of Simultaneous Polysubstance Use in Canadian Rave Attendees. Substance Use and Misuse, 2005, 40, 1525-1537.	0.7	113
27	Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 19115-19120.	3.3	251
28	Simultaneous and Sensitive Analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in Plasma after Oral Application of Small Doses of THC and Cannabis Extract. Journal of Analytical Toxicology, 2005, 29, 782-789.	1.7	116
29	The Effects of Cocaine and Heroin Use on Intubation Rates and Hospital Utilization in Patients With Acute Asthma Exacerbations. Chest, 2005, 128, 1951-1957.	0.4	65
30	The Recent Impact of Solid-Phase Synthesis on Medicinally Relevant Benzoannelated Oxygen Heterocycles. ACS Combinatorial Science, 2005, 7, 147-169.	3.3	103
31	Pharmacokinetics and Metabolism of the Plant Cannabinoids, î"9-Tetrahydrocannibinol, Cannabidiol and Cannabinol., 2005,, 657-690.		205
32	Medicinal Cannabis in Oncology Practice: Still a Bridge Too Far?. Journal of Clinical Oncology, 2005, 23, 2886-2891.	0.8	21
33	Emerging properties of cannabinoid medicines in management of multiple sclerosis. Trends in Neurosciences, 2005, 28, 272-276.	4.2	75
34	Is marihuana [THC] anti-carcinogenic?. Toxicon, 2005, 46, 357-359.	0.8	1
35	Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB Journal, 2006, 20, 2633-2635.	0.2	244
36	Comparison of Orally Administered Cannabis Extract and Delta-9-Tetrahydrocannabinol in Treating Patients With Cancer-Related Anorexia-Cachexia Syndrome: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial From the Cannabis-In-Cachexia-Study-Group. Journal of Clinical Oncology, 2006, 24, 3394-3400.	0.8	355
37	Targeting the CB2receptor for immune modulation. Expert Opinion on Therapeutic Targets, 2006, 10, 653-663.	1.5	56
39	Cannabinoids., 2006,, 289-337.		1
40	Conséquences à court et long terme d'une exposition prénatale au cannabis. Revue Sage - Femme, 2006 5, 95-103.	' 0.1	O

#	Article	IF	Citations
41	The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacological Reviews, 2006, 58, 389-462.	7.1	2,274
42	Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. International Immunopharmacology, 2006, 6, 656-665.	1.7	72
43	Cell–cell communication by Endocannabinoids during Immune Surveillance of the Central Nervous System. , 2006, 43, 281-305.		7
44	Altered regional blood volume in chronic cannabis smokers Experimental and Clinical Psychopharmacology, 2006, 14, 422-428.	1.3	34
45	Review of Biologic Matrices (Urine, Blood, Hair) as Indicators of Recent or Ongoing Cannabis Use. Therapeutic Drug Monitoring, 2006, 28, 155-163.	1.0	209
46	Severity of Drug Use, Initiation of Prenatal Care, and Maternalâ€Fetal Attachment in Pregnant Marijuana and Cocaine/Heroin Users. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2006, 35, 499-508.	0.2	23
49	Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology, 2006, 185, 524-528.	1.5	149
50	The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology, 2006, 188, 425-444.	1.5	441
51	Challenges of marijuana research. Brain, 2006, 129, 1081-1083.	3.7	8
52	Brain Neuroimaging in Cannabis Use: A Review. Journal of Neuropsychiatry and Clinical Neurosciences, 2006, 18, 318-332.	0.9	103
53	Characterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 850-857.	1.3	157
54	Ocular Hypotensive Effects of an Intratracheally Delivered Liposomal Δ9-Tetrahydrocannabinol Preparation in Rats. Journal of Ocular Pharmacology and Therapeutics, 2006, 22, 160-167.	0.6	16
55	The Neuropsychology of Cannabis and other Substance use in Schizophrenia: Review of the Literature and Critical Evaluation of Methodological Issues. Australian and New Zealand Journal of Psychiatry, 2007, 41, 869-884.	1.3	43
56	Pharmacokinetic Properties of Â9-Tetrahydrocannabinol in Serum and Oral Fluid. Journal of Analytical Toxicology, 2007, 31, 288-293.	1.7	96
57	Chemistry and Biological Activity of Tetrahydrocannabinol and its Derivatives. Topics in Heterocyclic Chemistry, 2007, , 1-42.	0.2	30
58	Dronabinol and Retinal Hemodynamics in Humans. American Journal of Ophthalmology, 2007, 143, 173-174.	1.7	26
59	Discovery of $\langle i \rangle N \langle i \rangle - \{(1 \langle i \rangle S \langle i \rangle , 2 \langle i \rangle S \langle i \rangle) - 2 - (3 - Cyanophenyl) - 3 - [4 - (2 - [\langle sup \rangle 18 \langle sup \rangle F] fluoroethoxy) phenyl] - 1 - methylpropyl} - 2 - methyl - 2 - [(5 - methylpyridin - 2 - yl) oxy] propanamide, a Cannabinoid - 1 Receptor Positron Emission Tomography Tracer Suitable for Clinical Use. Journal of Medicinal Chemistry, 2007, 50, 3427-3430.$	2.9	32
60	Medicinal Cannabis Does Not Influence the Clinical Pharmacokinetics of Irinotecan and Docetaxel. Oncologist, 2007, 12, 291-300.	1.9	62

#	ARTICLE	IF	Citations
61	Antibody-Catalyzed Oxidation of î"9-Tetrahydrocannabinol. Journal of the American Chemical Society, 2007, 129, 3698-3702.	6.6	8
62	Prenatal Cannabis Exposure Increases Heroin Seeking with Allostatic Changes in Limbic Enkephalin Systems in Adulthood. Biological Psychiatry, 2007, 61, 554-563.	0.7	131
63	History of Cannabis and Its Preparations in Saga, Science, and Sobriquet. Chemistry and Biodiversity, 2007, 4, 1614-1648.	1.0	400
64	Human Cannabinoid Pharmacokinetics. Chemistry and Biodiversity, 2007, 4, 1770-1804.	1.0	833
65	Deposition of cannabinoids in hair after long-term use of cannabis. Forensic Science International, 2007, 170, 46-50.	1.3	52
66	The treatment of spasticity with î"9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord, 2007, 45, 551-562.	0.9	60
67	Developing limits for driving under cannabis. Addiction, 2007, 102, 1910-1917.	1.7	165
68	Interpretation of Oral Fluid Tests for Drugs of Abuse. Annals of the New York Academy of Sciences, 2007, 1098, 51-103.	1.8	151
69	Acute and Non-acute Effects of Cannabis on Brain Functioning and Neuropsychological Performance. Neuropsychology Review, 2007, 17, 347-361.	2.5	122
70	Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69Âmg THC. Psychopharmacology, 2008, 201, 171-181.	1.5	62
71	Study of the structureâ€activity relationship for theoretical molecular descriptors using density functional theory and chemometric methods in cannabinoid metabolites. International Journal of Quantum Chemistry, 2008, 108, 2530-2539.	1.0	3
72	Driving under the influence of cannabis: a 10â€year study of age and gender differences in the concentrations of tetrahydrocannabinol in blood. Addiction, 2008, 103, 452-461.	1.7	83
73	Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. Journal of Neuroimmunology, 2008, 193, 120-129.	1.1	91
74	Post-training CB1 cannabinoid receptor agonist activation disrupts long-term consolidation of spatial memories in the hippocampus. Neuroscience, 2008, 151, 929-936.	1.1	46
75	Effect of illicit recreational drugs upon sleep: Cocaine, ecstasy and marijuana. Sleep Medicine Reviews, 2008, 12, 381-389.	3.8	253
76	Modelling of the concentrationâ€"effect relationship of THC on central nervous system parameters and heart rate â€" insight into its mechanisms of action and a tool for clinical research and development of cannabinoids. Journal of Psychopharmacology, 2008, 22, 717-726.	2.0	69
77	Therapeutic effects of î"9-THC and modafinil in a marmoset Parkinson model. European Neuropsychopharmacology, 2008, 18, 383-389.	0.3	49
78	Effects of acute oral î"9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. European Neuropsychopharmacology, 2008, 18, 569-577.	0.3	76

#	Article	IF	CITATIONS
79	Differences in regional blood volume during a 28-day period of abstinence in chronic cannabis smokers. European Neuropsychopharmacology, 2008, 18, 612-619.	0.3	46
80	Reduction of Congenital Nystagmus in a Patient after Smoking Cannabis. Strabismus, 2008, 16, 29-32.	0.4	16
81	Use of medical marijuana for treatment of severe intractable nausea after laparoscopic Roux-en-Y gastric bypass surgery. Surgery for Obesity and Related Diseases, 2008, 4, 550-551.	1.0	7
82	Eliciting Possible Reaction Equations and Metabolic Pathways Involving Orphan Metabolites. Journal of Chemical Information and Modeling, 2008, 48, 2335-2349.	2.5	23
83	Effect of intrapulmonary tetrahydrocannabinol administration in humans. Journal of Psychopharmacology, 2008, 22, 707-716.	2.0	119
84	Comparison of Cannabinoid Pharmacokinetic Properties in Occasional and Heavy Users Smoking a Marijuana or Placebo Joint. Journal of Analytical Toxicology, 2008, 32, 470-477.	1.7	98
85	Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opinion on Investigational Drugs, 2008, 17, 85-95.	1.9	74
86	Cannabinoid Concentrations in Spot Serum Samples 24-48 Hours After Discontinuation of Cannabis Smoking. Journal of Analytical Toxicology, 2008, 32, 160-164.	1.7	42
87	Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management, 2008, Volume 4, 245-259.	0.9	210
88	Urinary Excretion of 11-Nor-9-Carboxy-Î"9-Tetrahydrocannabinol in a Pregnant Woman Following Heavy, Chronic Cannabis Use. Journal of Analytical Toxicology, 2009, 33, 610-614.	1.7	12
89	The acute effects of synthetic intravenous î"9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychological Medicine, 2009, 39, 1607.	2.7	259
90	Investigating the Role of Serotonin in Visual Orientation Processing Using an â€~Ecstasy' (MDMA)-Based Research Model. Neuropsychobiology, 2009, 60, 204-212.	0.9	20
91	Hydroxylation and Further Oxidation of Î" ⁹ -Tetrahydrocannabinol by Alkane-Degrading Bacteria. Applied and Environmental Microbiology, 2009, 75, 7135-7141.	1.4	10
92	Studies on the metabolism of the Δ9â€tetrahydrocannabinol precursor Δ9â€tetrahydrocannabinolic acid A (Δ9â€THCAâ€A) in rat using LCâ€MS/MS, LCâ€QTOF MS and GCâ€MS techniques. Journal of Mass Spectrometry, 44, 1423-1433.	2009,	48
93	Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating \hat{l} 9-tetrahydrocannabinol. Psychopharmacology, 2009, 203, 219-228.	1.5	20
94	Biomarkers for the effects of cannabis and THC in healthy volunteers. British Journal of Clinical Pharmacology, 2009, 67, 5-21.	1.1	102
95	Systematic Review and Meta-analysis of Cannabis Treatment for Chronic Pain. Pain Medicine, 2009, 10, 1353-1368.	0.9	182
96	Effect of Δ ⁹ â€tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. British Journal of Pharmacology, 2009, 156, 153-162.	2.7	72

#	Article	IF	CITATIONS
97	Reposition of a Dislocated Shoulder Under Use of Cannabis. Wilderness and Environmental Medicine, 2009, 20, 301-302.	0.4	2
98	Marijuana Effectiveness as an HIV Self-Care Strategy. Clinical Nursing Research, 2009, 18, 172-193.	0.7	47
99	Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers. Journal of Psychopharmacology, 2009, 23, 633-644.	2.0	17
100	Cannabidiol: A Promising Drug for Neurodegenerative Disorders?. CNS Neuroscience and Therapeutics, 2009, 15, 65-75.	1.9	179
101	Age of Onset of Cannabis Use is Associated with Age of Onset of High-Risk Symptoms for Psychosis. Canadian Journal of Psychiatry, 2010, 55, 165-171.	0.9	60
102	Medicinal cannabis: is î"9–tetrahydrocannabinol necessary for all its effects?. Journal of Pharmacy and Pharmacology, 2010, 55, 1687-1694.	1.2	85
103	Human skin permeation of Δ8-tetrahydrocannabinol, cannabidiol and cannabinol. Journal of Pharmacy and Pharmacology, 2010, 56, 291-297.	1.2	87
104	Permeation of WIN 55,212-2, a potent cannabinoid receptor agonist, across human tracheo-bronchial tissue in vitro and rat nasal epithelium in vivo. Journal of Pharmacy and Pharmacology, 2010, 58, 1459-1465.	1.2	14
105	Arthritis and cannabinoids: HU-210 and Win-55,212â€"2 prevent IL-1 α-induced matrix degradation in bovine articular chondrocytes in-vitroâ€. Journal of Pharmacy and Pharmacology, 2010, 58, 351-358.	1.2	47
106	Sex, Drugs, and Cognition: Effects of Marijuana. Journal of Psychoactive Drugs, 2010, 42, 413-424.	1.0	54
108	Antidepressant-like effect of \hat{l} "9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L Pharmacology Biochemistry and Behavior, 2010, 95, 434-442.	1.3	205
109	Cannabis with high î"9-THC contents affects perception and visual selective attention acutely: An event-related potential study. Pharmacology Biochemistry and Behavior, 2010, 96, 67-74.	1.3	49
110	Cognitive mechanisms underlying risky decision-making in chronic cannabis users. Journal of Mathematical Psychology, 2010, 54, 28-38.	1.0	152
111	Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapyâ€induced nausea and vomiting. British Journal of Clinical Pharmacology, 2010, 70, 656-663.	1.1	113
112	Cannabis use in palliative care – an examination of the evidence and the implications for nurses. Journal of Clinical Nursing, 2010, 19, 2454-2462.	1.4	12
113	Medical Cannabis and Chronic Opioid Therapy. Journal of Pain and Palliative Care Pharmacotherapy, 2010, 24, 356-361.	0.5	11
114	Rimonabant-Induced î"9-Tetrahydrocannabinol Withdrawal in Rhesus Monkeys: Discriminative Stimulus Effects and Other Withdrawal Signs. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 347-356.	1.3	41
115	Disposition of Cannabichromene, Cannabidiol, and Â9-Tetrahydrocannabinol and its Metabolites in Mouse Brain following Marijuana Inhalation Determined by High-Performance Liquid Chromatography-Tandem Mass Spectrometry. Journal of Analytical Toxicology, 2010, 34, 516-520.	1.7	35

#	Article	IF	CITATIONS
116	Using cannabinoids in pain and palliative care. International Journal of Palliative Nursing, 2010, 16, 481-485.	0.2	18
117	Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Cmaj, 2010, 182, E694-E701.	0.9	342
118	Central nervous system effects of haloperidol on THC in healthy male volunteers. Journal of Psychopharmacology, 2010, 24, 1697-1708.	2.0	51
119	Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Î"9-tetrahydrocannabinolâ"†. Drug and Alcohol Dependence, 2010, 112, 126-133.	1.6	84
120	Revisiting the complex influences of cannabinoids on motor functions unravels pharmacodynamic differences between cannabinoid agonists. Neuropharmacology, 2010, 59, 503-510.	2.0	22
121	Chemistry of Cannabis. , 2010, , 1033-1084.		33
122	Drugs involved in drug-facilitated crimes – part II: Drugs of abuse, prescription and over-the-counter medications. A review. Annales Pharmaceutiques Francaises, 2010, 68, 319-331.	0.4	6
123	Pharmacodynamic and pharmacokinetic effects of the intravenous CB1 receptor agonist Org 26828 in healthy male volunteers. Journal of Psychopharmacology, 2010, 24, 1689-1696.	2.0	6
124	A Cannabinoid Ligand, Anandamide, Exacerbates Endotoxin-Induced Uveitis in Rabbits. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 545-552.	0.6	17
125	Maternal Cannabis Use Alters Ventral Striatal Dopamine D2 Gene Regulation in the Offspring. Biological Psychiatry, 2011, 70, 763-769.	0.7	215
126	Developmental neurotoxicity of abused drugs., 2011,, 341-353.		1
127	Refining the estimation of illicit drug consumptions from wastewater analysis: Co-analysis of prescription pharmaceuticals and uncertainty assessment. Water Research, 2011, 45, 4437-4448.	5.3	196
128	An Evidence-Based Review of Acute and Long-Term Effects of Cannabis Use on Executive Cognitive Functions. Journal of Addiction Medicine, 2011, 5, 1-8.	1.4	527
129	Scientific Opinion on the safety of hemp (Cannabis genus) for use as animal feed. EFSA Journal, 2011, 9, 2011.	0.9	39
130	The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys. British Journal of Pharmacology, 2011, 164, 655-666.	2.7	16
131	Enhanced Solubility, Stability, and Transcorneal Permeability of Delta-8-Tetrahydrocannabinol in the Presence of Cyclodextrins. AAPS PharmSciTech, 2011, 12, 723-731.	1.5	34
132	Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users. Analytical and Bioanalytical Chemistry, 2011, 400, 145-152.	1.9	22
133	Latest Approaches for the Treatment of Spasticity and Autonomic Dysreflexia in Chronic Spinal Cord Injury. Neurotherapeutics, 2011, 8, 274-282.	2.1	86

#	Article	IF	CITATIONS
134	Aryl hydrocarbon receptor-dependent upregulation of Cyp1b1 by TCDD and diesel exhaust particles in rat brain microvessels. Fluids and Barriers of the CNS, 2011, 8, 23.	2.4	43
135	Cannabinoids for Pain Management. Advances in Psychosomatic Medicine, 2011, 30, 125-138.	2.2	12
136	Cannabidiol, a Major Phytocannabinoid, As a Potent Atypical Inhibitor for CYP2D6. Drug Metabolism and Disposition, 2011, 39, 2049-2056.	1.7	125
137	Nonpsychotropic Cannabinoids, Abnormal Cannabidiol and Canabigerol-Dimethyl Heptyl, Act at Novel Cannabinoid Receptors to Reduce Intraocular Pressure. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 427-435.	0.6	22
138	Effects of cannabis on cognitive function in patients with multiple sclerosis. Neurology, 2011, 76, 1153-1160.	1.5	82
139	Dose-Related Modulation of Event-Related Potentials to Novel and Target Stimuli by Intravenous Δ9-THC in Humans. Neuropsychopharmacology, 2012, 37, 1632-1646.	2.8	89
140	Testing the effects of Δ9-THC and D-cycloserine on extinction of conditioned fear in humans. Journal of Psychopharmacology, 2012, 26, 471-478.	2.0	61
141	Heat Exposure of <i>Cannabis sativa </i> Extracts Affects the Pharmacokinetic and Metabolic Profile in Healthy Male Subjects. Planta Medica, 2012, 78, 686-691.	0.7	46
142	Naltrexone does not attenuate the effects of intravenous î"9-tetrahydrocannabinol in healthy humans. International Journal of Neuropsychopharmacology, 2012, 15, 1251-1264.	1.0	24
143	Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233. Journal of Neuro-Oncology, 2012, 110, 163-177.	1.4	31
144	Withdrawal from THC during adolescence: Sex differences in locomotor activity and anxiety. Behavioural Brain Research, 2012, 231, 48-59.	1.2	59
145	Impairment based legislative limits for driving under the influence of non-alcohol drugs in Norway. Forensic Science International, 2012, 219, 1-11.	1.3	133
147	Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: A meta-analysis Experimental and Clinical Psychopharmacology, 2012, 20, 420-429.	1.3	227
148	Severe Cannabinoid Intoxication in A Patient with Non-Small-Cell Lung Cancer. Journal of Palliative Care, 2012, 28, 60-61.	0.4	1
149	The intersection between cannabis and cancer in the United States. Critical Reviews in Oncology/Hematology, 2012, 83, 1-10.	2.0	54
150	Novel Δ ⁹ â€tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects. British Journal of Clinical Pharmacology, 2012, 74, 42-53.	1.1	64
151	The safety of studies with intravenous î"9-tetrahydrocannabinol in humans, with case histories. Psychopharmacology, 2012, 219, 885-896.	1.5	29
152	Characterizing smoking topography of cannabis in heavy users. Psychopharmacology, 2012, 220, 309-318.	1.5	41

#	Article	lF	Citations
153	Formulas Used by Tibetan Doctors at Menâ€Tseeâ€Khang in India for the Treatment of Neuropsychiatric Disorders and Their Correlation with Pharmacological Data. Phytotherapy Research, 2013, 27, 552-563.	2.8	16
154	Altered visual perception in long-term ecstasy (MDMA) users. Psychopharmacology, 2013, 229, 155-165.	1.5	9
155	Simultaneous and sensitive LC–MS/MS determination of tetrahydrocannabinol and metabolites in human plasma. Analytical and Bioanalytical Chemistry, 2013, 405, 1399-1406.	1.9	20
156	Recent advances in LC–MS/MS analysis of Δ9-tetrahydrocannabinol and its metabolites in biological matrices. Bioanalysis, 2013, 5, 2713-2731.	0.6	5
157	Controlled-Deactivation Cannabinergic Ligands. Journal of Medicinal Chemistry, 2013, 56, 10142-10157.	2.9	26
158	Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint. Analytical and Bioanalytical Chemistry, 2013, 405, 9791-9803.	1.9	58
159	The Medicinal Use of Cannabis and Cannabinoidsâ€"An International Cross-Sectional Survey on Administration Forms. Journal of Psychoactive Drugs, 2013, 45, 199-210.	1.0	189
160	Fast quantification of 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid (THCA) using microwave-accelerated derivatisation and gas chromatography–triple quadrupole mass spectrometry. Forensic Science International, 2013, 224, 90-95.	1.3	19
161	Acute effects of THC on time perception in frequent and infrequent cannabis users. Psychopharmacology, 2013, 226, 401-413.	1.5	76
162	Low-Dose Vaporized Cannabis Significantly Improves Neuropathic Pain. Journal of Pain, 2013, 14, 136-148.	0.7	236
163	Suppression by î"9-tetrahydrocannabinol of the primary immunoglobulin M response by human peripheral blood B cells is associated with impaired STAT3 activation. Toxicology, 2013, 310, 84-91.	2.0	9
164	Cannabinoids. Journal of Pain and Symptom Management, 2013, 46, 142-149.	0.6	32
165	Impaired NFAT and NFκB activation are involved in suppression of CD40 ligand expression by ΰ9-tetrahydrocannabinol in human CD4+ T cells. Toxicology and Applied Pharmacology, 2013, 273, 209-218.	1.3	18
166	Cannabis Effects on Driving Skills. Clinical Chemistry, 2013, 59, 478-492.	1.5	476
167	Role of Cannabinoids in Pain Management. , 2013, , 181-197.		23
168	Preparation and characterization of \hat{l} 'sup>9-tetrahydrocannabinol-loaded biodegradable polymeric microparticles and their antitumoral efficacy on cancer cell lines. Journal of Drug Targeting, 2013, 21, 710-718.	2.1	17
169	Cannabis affects people differently: inter-subject variation in the psychotogenic effects of î" ⁹ -tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers. Psychological Medicine, 2013, 43, 1255-1267.	2.7	51
170	Cannabidiol Is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C19. Drug Metabolism and Pharmacokinetics, 2013, 28, 332-338.	1.1	157

#	Article	IF	CITATIONS
172	Cannabinoids. , 0, , 249-266.		0
173	Usos LÃcito e IlÃcito dos Fármacos. Acta Medica Portuguesa, 2014, 27, 755-766.	0.2	7
175	Cannabis abuse and dependence. , 0, , 315-329.		0
176	"Noids―in a nutshell: everything you (don't) want to know about synthetic cannabimimetics. Advances in Dual Diagnosis, 2014, 7, 137-148.	0.3	21
177	Cannabis Cue Reactivity and Craving Among Never, Infrequent and Heavy Cannabis Users. Neuropsychopharmacology, 2014, 39, 1214-1221.	2.8	39
178	A service-level action research intervention to improve identification and treatment of cannabis and related mental health issues in young Indigenous Australians: a study protocol. BMJ Open, 2014, 4, e005689-e005689.	0.8	2
179	Can Physical Exercise or Food Deprivation Cause Release of Fatâ€Stored Cannabinoids?. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 467-471.	1.2	9
180	Miswiring the brain: Â9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway. EMBO Journal, 2014, 33, 668-685.	3.5	189
181	The influence of personality on the sensitivity to subjective effects of \hat{l} 9-tetrahydrocannabinol. Psychiatry Research, 2014, 220, 945-953.	1.7	3
182	Cannabis use: a perspective in relation to the proposed UK drugâ€driving legislation. Drug Testing and Analysis, 2014, 6, 143-154.	1.6	17
183	Treatment Acceptability, Stigma, and Legal Concerns of Medical Marijuana Are Affected by Method of Administration. Journal of Drug Issues, 2014, 44, 308-320.	0.6	5
184	Marijuana and lung diseases. Current Opinion in Pulmonary Medicine, 2014, 20, 173-179.	1.2	80
185	Exploring the Management of Cannabis Use Among Women and During Pregnancy. Addictive Disorders and Their Treatment, 2014, 13, 93-100.	0.5	7
186	A protocol for the delivery of cannabidiol (CBD) and combined CBD and â^†9-tetrahydrocannabinol (THC) by vaporisation. BMC Pharmacology & Empty (The combined CBD) and a few protocology (THC) by vaporisation.	1.0	43
187	Youth marijuana use. Current Opinion in Pediatrics, 2014, 26, 420-427.	1.0	30
188	Current knowledge on cannabinoids in oral fluid. Drug Testing and Analysis, 2014, 6, 88-111.	1.6	84
189	Alterations to global but not local motion processing in long-term ecstasy (MDMA) users. Psychopharmacology, 2014, 231, 2611-2622.	1.5	2
190	C-Ring Cannabinoid Lactones: A Novel Cannabinergic Chemotype. ACS Medicinal Chemistry Letters, 2014, 5, 400-404.	1.3	11

#	Article	IF	CITATIONS
191	î"9-Tetrahydrocannabinol Treatment During Human Monocyte Differentiation Reduces Macrophage Susceptibility to HIV-1 Infection. Journal of NeuroImmune Pharmacology, 2014, 9, 369-379.	2.1	34
192	Cannabis use and neurocognitive functioning in a non-clinical sample of users. Addictive Behaviors, 2014, 39, 994-999.	1.7	74
193	Medical Marijuana and Driving: a Review. Journal of Medical Toxicology, 2014, 10, 269-279.	0.8	68
194	Prevalence of synthetic cannabinoids in blood samples from Norwegian drivers suspected of impaired driving during a seven weeks period. Accident Analysis and Prevention, 2014, 62, 26-31.	3.0	64
195	Spice/K2 drugs – more than innocent substitutes for marijuana. International Journal of Neuropsychopharmacology, 2014, 17, 509-525.	1.0	79
196	Dronabinol and chronic pain: importance of mechanistic considerations. Expert Opinion on Pharmacotherapy, 2014, 15, 1525-1534.	0.9	29
197	Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification: Cannabis withdrawal syndrome and its correlation with delta-9-tetrahydrocannabinol and -metabolites in serum. Drug and Alcohol Dependence, 2014, 143, 189-197.	1.6	23
198	The Pharmacokinetics, Efficacy, Safety, and Ease of Use of a Novel Portable Metered-Dose Cannabis Inhaler in Patients With Chronic Neuropathic Pain: A Phase 1a Study. Journal of Pain and Palliative Care Pharmacotherapy, 2014, 28, 216-225.	0.5	57
199	A vapourized î"9-tetrahydrocannabinol (î"9-THC) delivery system part I: Development and validation of a pulmonary cannabinoid route of exposure for experimental pharmacology studies in rodents. Journal of Pharmacological and Toxicological Methods, 2014, 70, 120-127.	0.3	56
200	CP55,940 attenuates spatial memory retrieval in mice. Pharmacological Reports, 2014, 66, 931-936.	1.5	7
201	Design, synthesis and biological evaluation of novel 6H-benzo[c]chromen-6-one, and 7,8,9,10-tetrahydro-benzo[c]chromen-6-one derivatives as potential cholinesterase inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 5141-5154.	1.4	34
202	A rare case of cannabis hyperemesis syndrome relieved by hot water bathing. Clinical Medicine, 2014, 14, 86-87.	0.8	9
203	Increased CB2 mRNA and anandamide in human blood after cessation of cannabis abuse. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 691-695.	1.4	16
204	Neuronal substrates and functional consequences of prenatal cannabis exposure. European Child and Adolescent Psychiatry, 2014, 23, 931-941.	2.8	103
205	Analysis of \hat{l} "9-tetrahydrocannabinol Driving Under the Influence of Drugs Cases in Colorado from January 2011 to February 2014. Journal of Analytical Toxicology, 2014, 38, 575-581.	1.7	25
206	The impact of recreational MDMA â€~ecstasy' use on global form processing. Journal of Psychopharmacology, 2014, 28, 1018-1029.	2.0	3
207	Medical Marijuana in the Workplace. Journal of Occupational and Environmental Medicine, 2015, 57, 518-525.	0.9	27
208	Cannabis Smoking in 2015. Chest, 2015, 148, 596-606.	0.4	40

#	Article	IF	CITATIONS
209	Scientific Opinion on the risks for human health related to the presence of tetrahydrocannabinol (THC) in milk and other food of animal origin. EFSA Journal, 2015, 13, 4141.	0.9	42
210	Finding cannabinoids in hair does not prove cannabis consumption. Scientific Reports, 2015, 5, 14906.	1.6	51
212	Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been …. Headache, 2015, 55, 885-916.	1.8	153
213	Î"9-Tetrahydrocannabinol (THC) enhances lipopolysaccharide-stimulated tissue factor in human monocytes and monocyte-derived microvesicles. Journal of Inflammation, 2015, 12, 39.	1.5	18
214	The Rapidly Increasing Trend of Cannabis Use in Burn Injury. Journal of Burn Care and Research, 2015, 36, e12-e17.	0.2	25
216	Cannabis sintético: aspectos toxicológicos, usos clÃnicos y droga de diseño. Revista Facultad De Medicina, 2015, 63, 501-510.	0.0	5
217	Updates on Nutraceutical Sleep Therapeutics and Investigational Research. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-9.	0.5	20
218	Alternations in Cholesterol and Fatty Acids Composition in Egg Yolk of Rhode Island Red x Fyoumi Hens Fed with Hemp Seeds (<i>Cannabis sativa</i> L.). Journal of Chemistry, 2015, 2015, 1-6.	0.9	22
219	Half-Baked â€" The Retail Promotion of Marijuana Edibles. New England Journal of Medicine, 2015, 372, 989-991.	13.9	88
220	Patterns of underlying causes of work-related traumatic fatalities $\hat{a} \in \mathbb{C}$ Comparison between small and larger companies in British Columbia. Safety Science, 2015, 71, 197-204.	2.6	13
221	Using a Group-Based Trajectory Approach to Assess Risk and Protective Factors of Marijuana Use. Journal of Drug Issues, 2015, 45, 4-21.	0.6	13
222	Psychosis and Severe Rhabdomyolysis Associated with Synthetic Cannabinoid Use. Clinical Schizophrenia and Related Psychoses, 2015, 8, 205-208.	1.4	40
223	Proximate composition, phytochemical screening, GC-MS studies of biologically active cannabinoids and antimicrobial activities of Cannabis indica. Asian Pacific Journal of Tropical Disease, 2015, 5, 897-902.	0.5	15
224	Nonsmoker Exposure to Secondhand Cannabis Smoke. III. Oral Fluid and Blood Drug Concentrations and Corresponding Subjective Effects. Journal of Analytical Toxicology, 2015, 39, 497-509.	1.7	45
225	An on-line stacking capillary electrophoresis method for the analysis of î"9-tetrahydrocannabinol and its metabolites. Journal of Chromatography A, 2015, 1426, 226-232.	1.8	10
226	Chemical identification of cannabinoids in street marijuana samples using electrospray ionization FT-ICR mass spectrometry. Analytical Methods, 2015, 7, 1415-1424.	1.3	32
227	Functional magnetic resonance brain imaging of executive cognitive performance in young first-episode schizophrenia patients and age-matched long-term cannabis users. Neurology Psychiatry and Brain Research, 2015, 21, 51-63.	2.0	2
228	Medical marijuana for cancer. Ca-A Cancer Journal for Clinicians, 2015, 65, 109-122.	157.7	111

#	ARTICLE	IF	Citations
229	Early Withdrawal Effects in a Heavy Cannabis Smoker During Hemodialysis. Biological Psychiatry, 2015, 77, e25-e26.	0.7	4
230	New Insights into Antimetastatic and Antiangiogenic Effects of Cannabinoids. International Review of Cell and Molecular Biology, 2015, 314, 43-116.	1.6	15
231	Activation of type-1 cannabinoid receptor shifts the balance between excitation and inhibition towards excitation in layer II/III pyramidal neurons of the rat prelimbic cortex. Pflugers Archiv European Journal of Physiology, 2015, 467, 1551-1564.	1.3	23
232	Chronic cannabis use and ERP correlates of visual selective attention during the performance of a flanker go/nogo task. Biological Psychology, 2015, 110, 115-125.	1.1	15
233	Impaired learning from errors in cannabis users: Dorsal anterior cingulate cortex and hippocampus hypoactivity. Drug and Alcohol Dependence, 2015, 155, 175-182.	1.6	40
234	Persistent effects of chronic Δ9-THC exposure on motor impulsivity in rats. Psychopharmacology, 2015, 232, 3033-3043.	1.5	41
235	Comparative effects of pulmonary and parenteral l'9-tetrahydrocannabinol exposure on extinction of opiate-induced conditioned aversion in rats. Psychopharmacology, 2015, 232, 1655-1665.	1.5	9
236	The Implications of Marijuana Legalization in Colorado. JAMA - Journal of the American Medical Association, 2015, 313, 241.	3.8	159
238	Smoke Your Troubles Away: Exploring the Effects of Death Cognitions on Cannabis Craving and Consumption. Journal of Psychoactive Drugs, 2015, 47, 91-99.	1.0	8
239	Cannabis: The never-ending, nefarious nepenthe of the 21st century: What should the clinician know?. Disease-a-Month, 2015, 61, 118-175.	0.4	14
240	Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy. Journal of Pain, 2015, 16, 616-627.	0.7	164
241	Medical Marijuana. Journal of Developmental and Behavioral Pediatrics, 2015, 36, 115-123.	0.6	66
242	Non-Smoker Exposure to Secondhand Cannabis Smoke. I. Urine Screening and Confirmation Results. Journal of Analytical Toxicology, 2015, 39, 1-12.	1.7	57
243	Examination of the Role of the Combination of Alcohol and Cannabis in South Australian Road Crashes. Traffic Injury Prevention, 2015, 16, 443-449.	0.6	9
244	Dose-dependent effects of cannabis on the neural correlates of error monitoring in frequent cannabis users. European Neuropsychopharmacology, 2015, 25, 1943-1953.	0.3	14
245	What to make of cannabis and cognition in MS: In search of clarity amidst the haze. Multiple Sclerosis Journal, 2015, 21, 1755-1760.	1.4	15
246	Medical Marijuana for Digestive Disorders: High Time to Prescribe?. American Journal of Gastroenterology, 2015, 110, 208-214.	0.2	47
247	Probing the Carboxyester Side Chain in Controlled Deactivation (â^')-Î" ⁸ -Tetrahydrocannabinols. Journal of Medicinal Chemistry, 2015, 58, 665-681.	2.9	26

#	ARTICLE	IF	Citations
248	Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS. HIV/AIDS - Research and Palliative Care, 2016, 8, 37.	0.4	31
249	Quality Control of Traditional Cannabis Tinctures: Pattern, Markers, and Stability. Scientia Pharmaceutica, 2016, 84, 567-584.	0.7	29
250	Tasty THC: Promises and Challenges of Cannabis Edibles. , 2016, 2016, .		112
251	History of Illicit Stimulant Use Is Not Associated with Long-Lasting Changes in Learning of Fine Motor Skills in Humans. Neural Plasticity, 2016, 2016, 1-11.	1.0	4
252	Stroke from Vasospasm due to Marijuana Use: Can Cannabis Synergistically with Other Medications Trigger Cerebral Vasospasm?. Case Reports in Neurological Medicine, 2016, 2016, 1-4.	0.3	9
253	A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis. Journal of Pain Research, 2016, Volume 9, 587-598.	0.8	38
254	Bioavailability study of dronabinol oral solution versus dronabinol capsules in healthy volunteers. Clinical Pharmacology: Advances and Applications, 2016, Volume 8, 155-162.	0.8	17
255	A User's Guide to Cannabinoid Therapies in Oncology. Current Oncology, 2016, 23, 398-406.	0.9	60
256	Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues. Journal of Medicinal Chemistry, 2016, 59, 6903-6919.	2.9	20
257	Acute effects of cocaine and cannabis on response inhibition in humans: an ERP investigation. Addiction Biology, 2016, 21, 1186-1198.	1.4	18
258	Accidental cannabis poisoning in the elderly. Wiener Klinische Wochenschrift, 2016, 128, 548-552.	1.0	7
259	Risk Factors for Driving After and During Marijuana Use. Journal of Studies on Alcohol and Drugs, 2016, 77, 309-316.	0.6	43
260	Cannabis and Amphetamine-type Stimulant-induced Psychoses: A Systematic Overview. Addictive Disorders and Their Treatment, 2016, 15, 190-200.	0.5	8
261	Objective Testing. Child and Adolescent Psychiatric Clinics of North America, 2016, 25, 549-565.	1.0	110
262	Sex and age specific effects of delta-9-tetrahydrocannabinol during the periadolescent period in the rat: The unique susceptibility of the prepubescent animal. Neurotoxicology and Teratology, 2016, 58, 88-100.	1.2	49
263	"Those edibles hit hard― Exploration of Twitter data on cannabis edibles in the U.S. Drug and Alcohol Dependence, 2016, 164, 64-70.	1.6	102
264	Gender Differences in Internalizing Symptoms and Suicide Risk Among Men and Women Seeking Treatment for Cannabis Use Disorder from Late Adolescence to Middle Adulthood. Journal of Substance Abuse Treatment, 2016, 66, 16-22.	1.5	33
265	A Case Report of Cannabis Induced Hemoptysis. Medicine (United States), 2016, 95, e3232.	0.4	16

#	Article	IF	CITATIONS
266	Adults with a history of illicit amphetamine use exhibit abnormal substantia nigra morphology and parkinsonism. Parkinsonism and Related Disorders, 2016, 25, 27-32.	1.1	35
267	Fatty Acid Binding Proteinâ€1 (FABP1) and the Human FABP1 T94A Variant: Roles in the Endocannabinoid System and Dyslipidemias. Lipids, 2016, 51, 655-676.	0.7	41
268	Opposite effects of cannabis and cocaine on performance monitoring. European Neuropsychopharmacology, 2016, 26, 1127-1139.	0.3	15
269	Pharmacokinetics of (synthetic) cannabinoids in pigs and their relevance for clinical and forensic toxicology. Toxicology Letters, 2016, 253, 7-16.	0.4	33
270	Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products. Clinical Pharmacokinetics, 2016, 55, 1353-1368.	1.6	114
271	Development and validation of an automated liquid-liquid extraction GC/MS method for the determination of THC, 11-OH-THC, and free THC-carboxylic acid (THC-COOH) from blood serum. Analytical and Bioanalytical Chemistry, 2016, 408, 4379-4388.	1.9	30
272	Cannabis Hyperemesis Syndrome in the Emergency Department: How Can a Specialized Addiction Team Be Useful? A Pilot Study. Journal of Emergency Medicine, 2016, 51, 544-551.	0.3	16
273	Effective treatment of spasticity using dronabinol in pediatric palliative care. European Journal of Paediatric Neurology, 2016, 20, 898-903.	0.7	37
274	Effects of Medical Marijuana on Migraine Headache Frequency in an Adult Population. Pharmacotherapy, 2016, 36, 505-510.	1.2	71
275	Prenatal cannabis exposure - The "first hit―to the endocannabinoid system. Neurotoxicology and Teratology, 2016, 58, 5-14.	1.2	94
276	Can You Pass the Acid Test? Critical Review and Novel Therapeutic Perspectives of î" ⁹ -Tetrahydrocannabinolic Acid A. Cannabis and Cannabinoid Research, 2016, 1, 124-130.	1.5	73
277	FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein. Biochemistry, 2016, 55, 5243-5255.	1.2	47
278	Risk for involvement in road traffic crash during acute cannabis intoxication. Addiction, 2016, 111, 1492-1495.	1.7	26
279	Development of Loop-Mediated Isothermal Amplification (LAMP) Assay for Rapid Detection of & lt;i>Cannabis sativa. Biological and Pharmaceutical Bulletin, 2016, 39, 1144-1149.	0.6	23
280	Characterization of edible marijuana product exposures reported to United States poison centers. Clinical Toxicology, 2016, 54, 840-846.	0.8	75
281	Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Translational Psychiatry, 2016, 6, e920-e920.	2.4	116
282	Pharmacology of Legal and Illicit Drugs. , 2016, , 660-666.		1
283	<scp>FABP</scp> â€1 gene ablation impacts brain endocannabinoid system in male mice. Journal of Neurochemistry, 2016, 138, 407-422.	2.1	29

#	Article	IF	CITATIONS
284	Marijuana and Cannabinoids for Pain. , 2016, , 87-109.		1
285	MicroRNA let-7d is a target of cannabinoid CB 1 receptor and controls cannabinoid signaling. Neuropharmacology, 2016, 108, 345-352.	2.0	23
286	An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease. Journal of Pain, 2016, 17, 982-1000.	0.7	72
287	Acute effects of cocaine and cannabis on reversal learning as a function of COMT and DRD2 genotype. Psychopharmacology, 2016, 233, 199-211.	1.5	20
288	High prevalence of cannabis use among Aka foragers of the Congo Basin and its possible relationship to helminthiasis. American Journal of Human Biology, 2016, 28, 5-15.	0.8	29
289	Lack of hippocampal CB1 receptor desensitization by Δ9-tetrahydrocannabinol in aged mice and by low doses of JZL 184. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 603-612.	1.4	17
290	Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome. Clinical Pharmacokinetics, 2016, 55, 807-812.	1.6	36
291	Metabolomics of \hat{l} " < sup > 9 < / sup > -tetrahydrocannabinol: implications in toxicity. Drug Metabolism Reviews, 2016, 48, 80-87.	1.5	67
292	Cannabis : les nouveaux défis du biologiste. Revue Francophone Des Laboratoires, 2016, 2016, 43-50.	0.0	0
293	Effect of JWH-250, JWH-073 and their interaction on "tetradâ€, sensorimotor, neurological and neurochemical responses in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 67, 31-50.	2.5	62
294	Colorado Cannabis Legalization and Its Effect on Emergency Care. Annals of Emergency Medicine, 2016, 68, 71-75.	0.3	79
295	Cannabis in Pain Treatment: Clinical and Research Considerations. Journal of Pain, 2016, 17, 654-668.	0.7	85
296	The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. Journal of Psychopharmacology, 2016, 30, 140-151.	2.0	69
297	Controlled release tablet formulation containing natural î" ⁹ -tetrahydrocannabinol. Drug Development and Industrial Pharmacy, 2016, 42, 1158-1164.	0.9	3
298	The pharmacokinetic disposition of delta-9-tetrahydrocannabinol and its metabolite in elderly patients with dementia—role of differential presystemic conversion?. Psychopharmacology, 2016, 233, 157-158.	1.5	1
299	Persistent inhibitory circuit defects and disrupted social behaviour following in utero exogenous cannabinoid exposure. Molecular Psychiatry, 2017, 22, 56-67.	4.1	59
300	Embattled cannabis: pharmacological, medical, recreational, and adverse effects aspects. Journal of Substance Use, 2017, 22, 236-239.	0.3	2
301	Metabolic patterns of JWHâ€210, RCSâ€4, and THC in pig urine elucidated using LCâ€HRâ€MS/MS: Do they reflect patterns in humans?. Drug Testing and Analysis, 2017, 9, 613-625.	it _{1.6}	10

#	ARTICLE	IF	CITATIONS
302	New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking. European Journal of Medicinal Chemistry, 2017, 127, 398-412.	2.6	15
303	Analysis of cannabinoids by liquid chromatography–mass spectrometry in milk, liver and hemp seed to ensure food safety. Food Chemistry, 2017, 228, 177-185.	4.2	29
304	Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy and Behavior, 2017, 70, 313-318.	0.9	148
305	The current status of artisanal cannabis for the treatment of epilepsy in the United States. Epilepsy and Behavior, 2017, 70, 328-333.	0.9	56
306	Consumer use and understanding of labelling information on edible marijuana products sold for recreational use in the states of Colorado and Washington. International Journal of Drug Policy, 2017, 43, 57-66.	1.6	36
307	Cannabidiol: State of the art and new challenges for therapeutic applications. , 2017, 175, 133-150.		410
308	Recognizing and regulating cannabis as a temptation good. International Journal of Drug Policy, 2017, 42, 50-56.	1.6	39
309	Can we make cannabis safer?. Lancet Psychiatry,the, 2017, 4, 643-648.	3.7	114
310	Population pharmacokinetics model of THC used by pulmonary route in occasional cannabis smokers. Journal of Pharmacological and Toxicological Methods, 2017, 85, 49-54.	0.3	10
311	Occurrence and fate of illicit drugs and pharmaceuticals in wastewater from two wastewater treatment plants in Costa Rica. Science of the Total Environment, 2017, 599-600, 98-107.	3.9	63
312	The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease. Behavioural Pharmacology, 2017, 28, 142-160.	0.8	37
313	Marijuana Use in Pregnancy: Concerns in an Evolving Era. Journal of Midwifery and Women's Health, 2017, 62, 363-367.	0.7	10
314	Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?. Depression and Anxiety, 2017, 34, 1006-1017.	2.0	73
316	Designing microorganisms for heterologous biosynthesis of cannabinoids. FEMS Yeast Research, 2017, 17, .	1.1	54
317	Cannabis: Exercise performance and sport. A systematic review. Journal of Science and Medicine in Sport, 2017, 20, 825-829.	0.6	40
318	Association between cannabis use and methadone maintenance treatment outcomes: an investigation into sex differences. Biology of Sex Differences, 2017, 8, 8.	1.8	30
319	The impact of current cannabis use on general cognitive function in people with psychotic illness. Schizophrenia Research, 2017, 190, 164-171.	1.1	6
320	How four U.S. states are regulating recreational marijuana edibles. International Journal of Drug Policy, 2017, 43, 83-90.	1.6	25

#	Article	IF	CITATIONS
321	Cannabis for Pain and Headaches: Primer. Current Pain and Headache Reports, 2017, 21, 19.	1.3	15
322	The arguments for and against cannabinoids application in glaucomatous retinopathy. Biomedicine and Pharmacotherapy, 2017, 86, 620-627.	2.5	22
323	Cannabis and Breastfeeding. Breastfeeding Medicine, 2017, 12, 580-581.	0.8	7
324	Common marijuana-related cases encountered in the emergency department. American Journal of Health-System Pharmacy, 2017, 74, 1904-1908.	0.5	16
325	Cannabinoids concentration variability in cannabis olive oil galenic preparationsâ€. Journal of Pharmacy and Pharmacology, 2017, 70, 143-149.	1.2	59
326	Medical Cannabinoids in Children and Adolescents: A Systematic Review. Pediatrics, 2017, 140, .	1.0	103
327	Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience. Clinical Neuropharmacology, 2017, 40, 268-272.	0.2	57
328	Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration. Journal of Controlled Release, 2017, 266, 1-7.	4.8	77
329	Is 2â€Hydroxypropylâ€Î²â€cyclodextrin a Suitable Carrier for Central Administration of Δ ⁹ â€Tetrahydrocannabinol? Preclinical Evidence. Drug Development Research, 2017, 78, 411-419.	1.4	0
330	Medical Cannabis in Serbia: The Survey of Knowledge and Attitudes in an Urban Adult Population. Journal of Psychoactive Drugs, 2017, 49, 217-224.	1.0	9
331	A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics. Cancer Chemotherapy and Pharmacology, 2017, 80, 441-449.	1.1	96
332	An (Un)Fortune Cookie. Pediatric Emergency Care, 2017, 33, 811-814.	0.5	2
333	Effects of alprazolam and cannabinoid-related compounds in an animal model of panic attack. Behavioural Brain Research, 2017, 317, 508-514.	1.2	6
334	Rapid identification of drug-type strains in Cannabis sativa using loop-mediated isothermal amplification assay. Journal of Natural Medicines, 2017, 71, 86-95.	1.1	16
335	Determination of cannabinoids in hemp nut products in Taiwan by HPLCâ€MS/MS coupled with chemometric analysis: quality evaluation and a pilot human study. Drug Testing and Analysis, 2017, 9, 888-897.	1.6	21
336	Medical cannabis: Another piece in the mosaic of autoimmunity?. Clinical Pharmacology and Therapeutics, 2017, 101, 230-238.	2.3	36
337	Cannabis, alcohol use, psychological distress, and decision-making style. Journal of Clinical and Experimental Neuropsychology, 2017, 39, 670-681.	0.8	6
338	Cannabis and Traffic Accidents. , 2017, , 234-243.		0

#	Article	IF	CITATIONS
339	Medical Marijuana in Children and Adolescents: An Updated Review for Psychopharmacologists. Child and Adolescent Psychopharmacology News, 2017, 22, 1-8,10.	0.1	1
340	Cannabidiol and Multiple Sclerosis. , 2017, , 893-904.		3
341	Treatment of acute cannabinoid overdose with naloxone infusion. Toxicology Communications, 2017, 1, 29-33.	0.3	7
342	Cannabis Induced Psychopathology. Journal of Addiction Research & Therapy, 2017, S11, .	0.2	0
343	Developmental Neurotoxicity of Abused Drugs. , 2017, , 413-429.		0
344	Recent legalization of cannabis use: effects on sleep, health, and workplace safety. Nature and Science of Sleep, 2017, Volume 9, 249-251.	1.4	15
345	Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?. Journal of Epilepsy Research, 2017, 7, 61-76.	0.1	176
346	Chronic Cannabis Abuse and ThyroidÂFunction. , 2017, , 461-465.		0
347	Medical Marijuana Use in Older Adults. Journal of the American Geriatrics Society, 2018, 66, 859-863.	1.3	39
348	A naturalistic examination of the perceived effects of cannabis on negative affect. Journal of Affective Disorders, 2018, 235, 198-205.	2.0	80
349	Synthesis, Pharmacological Evaluation, and Docking Studies of Novel Pyridazinoneâ€Based Cannabinoid Receptor Typeâ€2 Ligands. ChemMedChem, 2018, 13, 1102-1114.	1.6	1
350	A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains. Cannabis and Cannabinoid Research, 2018, 3, 35-44.	1.5	31
351	Cannabinoid Disposition After Human Intraperitoneal Use: An Insight Into Intraperitoneal Pharmacokinetic Properties in Metastatic Cancer. Clinical Therapeutics, 2018, 40, 1442-1447.	1.1	12
352	PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers. Journal of Pharmaceutical Sciences, 2018, 107, 1423-1429.	1.6	70
353	Pharmacokinetic Characterization of 11-nor-9-carboxy-î"9-tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults. Journal of Analytical Toxicology, 2018, 42, 232-247.	1.7	16
354	Residual effects of cannabis use in adolescent and adult brains $\hat{a}\in$ " A meta-analysis of fMRI studies. Neuroscience and Biobehavioral Reviews, 2018, 88, 26-41.	2.9	69
355	Zebrafish models relevant to studying central opioid and endocannabinoid systems. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 86, 301-312.	2.5	48
356	Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay. Transplantation Proceedings, 2018, 50, 461-464.	0.3	56

#	ARTICLE	IF	Citations
357	î"9-Tetrahydrocannabinol induces endocannabinoid accumulation in mouse hepatocytes: antagonism by Fabp1 gene ablation. Journal of Lipid Research, 2018, 59, 646-657.	2.0	14
358	Marijuana Misadventures in Children. Pediatric Emergency Care, 2018, 34, 457-462.	0.5	19
359	The association of cannabis use on inpatient psychiatric hospital outcomes. American Journal of Drug and Alcohol Abuse, 2018, 44, 73-84.	1.1	8
360	Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology. Psychopharmacology, 2018, 235, 447-458.	1.5	26
361	What do we tell patients with coronary artery disease about marijuana use?. Coronary Artery Disease, 2018, 29, 1-3.	0.3	0
362	Cannabis use during pregnancy: Pharmacokinetics and effects on child development., 2018, 182, 133-151.		180
363	Psychopharmacological advances in eating disorders. Expert Review of Clinical Pharmacology, 2018, 11, 95-108.	1.3	84
364	Consumers' Perceptions of Edible Marijuana Products for Recreational Use: Likes, Dislikes, and Reasons for Use. Substance Use and Misuse, 2018, 53, 541-547.	0.7	41
365	Relating Observed Psychoactive Effects to the Plasma Concentrations of Delta-9-Tetrahydrocannabinol and Its Active Metabolite: An Effect-Compartment Modeling Approach. Journal of Pharmaceutical Sciences, 2018, 107, 745-755.	1.6	9
366	Cardiovascular Complications of Marijuana and Related Substances: A Review. Cardiology and Therapy, 2018, 7, 45-59.	1.1	127
367	Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma. Oncologist, 2018, 23, 306-315.	1.9	56
368	Singleâ€Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology. Clinical Pharmacology in Drug Development, 2018, 7, 751-758.	0.8	46
369	Patient Counseling Guidelines for the Use of Cannabis for the Treatment of Chemotherapy-Induced Nausea/Vomiting and Chronic Pain. Journal of Pain and Palliative Care Pharmacotherapy, 2018, 32, 216-225.	0.5	7
370	Cannabis Use Among Remote Indigenous Australians: Opportunities to Support Change Identified in Two Waves of Sampling. Frontiers in Public Health, 2018, 6, 310.	1.3	0
372	Cannabinoids and Pain: New Insights From Old Molecules. Frontiers in Pharmacology, 2018, 9, 1259.	1.6	202
373	Structural and Functional Interaction of î" ⁹ -Tetrahydrocannabinol with Liver Fatty Acid Binding Protein (FABP1). Biochemistry, 2018, 57, 6027-6042.	1.2	8
374	Cannabinoid Delivery Systems for Pain and Inflammation Treatment. Molecules, 2018, 23, 2478.	1.7	182
375	The acute effects of cannabis on human executive function. Behavioural Pharmacology, 2018, 29, 605-616.	0.8	24

#	Article	IF	Citations
376	Cannabis use and driving-related performance in young recreational users: a within-subject randomized clinical trial. CMAJ Open, 2018, 6, E453-E462.	1.1	44
377	Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Translational Psychiatry, 2018, 8, 181.	2.4	102
378	E-cigarettes—An unintended illicit drug delivery system. Drug and Alcohol Dependence, 2018, 192, 98-111.	1.6	90
379	Marijuana Use During Pregnancy and Breastfeeding: Implications for Neonatal and Childhood Outcomes. Pediatrics, 2018, 142, .	1.0	174
380	Evaluation of reinforcing and aversive effects of voluntary î"9-tetrahydrocannabinol ingestion in rats. Neuropharmacology, 2018, 137, 133-140.	2.0	18
381	Part I: Current Legislation, Scientific Literature Review, and Nursing Implications. Journal of Nursing Regulation, 2018, 9, S6-S21.	1.6	1
382	Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects. British Journal of Clinical Pharmacology, 2018, 84, 2468-2476.	1.1	85
383	Does Marijuana Contribute to Intimate Partner Aggression? Temporal Effects in a Community Sample of Marijuana-Using Couples. Journal of Studies on Alcohol and Drugs, 2018, 79, 432-440.	0.6	18
384	Cannabis use and the development of tolerance: a systematic review of human evidence. Neuroscience and Biobehavioral Reviews, 2018, 93, 1-25.	2.9	101
385	Role of Cannabinoids in Pain Management. , 2018, , 509-520.e2.		2
386	Driving While Stoned: Issues and Policy Options. SSRN Electronic Journal, 2018, , .	0.4	3
387	Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis. Mental Health Clinician, 2018, 8, 110-115.	0.5	35
388	Pharmacokinetics and Tolerability of î"9-THC-Hemisuccinate in a Suppository Formulation as an Alternative to Capsules for the Systemic Delivery of î"9-THC. Medical Cannabis and Cannabinoids, 2018, 1, 44-53.	1.2	7
389	The Pediatrician and Marijuana. Advances in Pediatrics, 2018, 65, 159-171.	0.5	2
390	Enhancing the Therapeutic Efficacy of Cancer Treatment With Cannabinoids. Frontiers in Oncology, 2018, 8, 114.	1.3	34
391	Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. Scientific Reports, 2018, 8, 10154.	1.6	41
392	Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)—a pilot study. European Journal of Clinical Pharmacology, 2018, 74, 1427-1436.	0.8	27
393	Irinotecan and î"9-Tetrahydrocannabinol Interactions in Rat Liver: A Preliminary Evaluation Using Biochemical and Genotoxicity Markers. Molecules, 2018, 23, 1332.	1.7	11

#	Article	IF	CITATIONS
394	Medical Marijuana Education in APRN Nursing Programs. Journal of Nursing Regulation, 2018, 9, S33-S38.	1.6	2
396	Effect of repeated juvenile exposure to Δ9‑tetrahydrocannabinol on anxiety-related behavior and social interactions in adolescent rats. Neurotoxicology and Teratology, 2018, 69, 11-20.	1.2	8
397	The pharmacokinetics and the pharmacodynamics of cannabinoids. British Journal of Clinical Pharmacology, 2018, 84, 2477-2482.	1.1	422
398	Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer. Therapeutics and Clinical Risk Management, 2018, Volume 14, 643-651.	0.9	86
399	The pitfalls of per se thresholds in accurately identifying acute cannabis intoxication at autopsy. Forensic Science, Medicine, and Pathology, 2018, 14, 497-502.	0.6	0
400	Affect and cannabis use in daily life: a review and recommendations for future research. Drug and Alcohol Dependence, 2018, 191, 223-233.	1.6	65
401	Marijuana Use by Breastfeeding Mothers and Cannabinoid Concentrations in Breast Milk. Pediatrics, 2018, 142, .	1.0	128
402	Wastewater-based epidemiology in low Human Development Index states: bias in consumption monitoring of illicit drugs. Environmental Science and Pollution Research, 2018, 25, 27819-27838.	2.7	15
403	Effects of Δ9-tetrahydrocannabinol on irinotecan-induced clinical effects in rats. Chemico-Biological Interactions, 2018, 294, 128-134.	1.7	8
404	Reinforcing effects of opioid/cannabinoid mixtures in rhesus monkeys responding under a food/drug choice procedure. Psychopharmacology, 2018, 235, 2357-2365.	1.5	20
405	Joint and separate exposure to alcohol and \hat{a}^{\dagger} 9-tetrahydrocannabinol produced distinct effects on glucose and insulin homeostasis in male rats. Scientific Reports, 2019, 9, 12025.	1.6	11
406	Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy. Drugs, 2019, 79, 1435-1454.	4.9	101
407	Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents. Handbook of Experimental Pharmacology, 2019, 258, 355-372.	0.9	5
408	Aversiveness and Meaningfulness of Uncomfortable Experiences with Edible Cannabis. Journal of Psychoactive Drugs, 2019, 51, 413-420.	1.0	7
409	Cannabis and the liver: Things you wanted to know but were afraid to ask. Canadian Liver Journal, 2019, 2, 51-57.	0.3	6
410	Total and differential white blood cell count in cannabis users: results from the cross-sectional National Health and Nutrition Examination Survey, 2005–2016. Journal of Cannabis Research, 2019, 1, .	1.5	6
411	Zebrafish as a High-Throughput In Vivo Model for Testing the Bioactivity of Cannabinoids. , 2019, , .		1
412	Cannabis and Cannabinoids: Kinetics and Interactions. American Journal of Medicine, 2019, 132, 1266-1270.	0.6	62

#	Article	IF	Citations
413	Flavonoid Derivative of Cannabis Demonstrates Therapeutic Potential in Preclinical Models of Metastatic Pancreatic Cancer. Frontiers in Oncology, 2019, 9, 660.	1.3	29
414	Coming off cannabis: a cognitive and magnetic resonance imaging study in patients with multiple sclerosis. Brain, 2019, 142, 2800-2812.	3.7	23
415	Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia, 2019, 60, 1586-1592.	2.6	83
416	Interest of adjusting urine cannabinoids to creatinine level to monitor cannabis cessation therapy in heavy smokers with psychiatric disorders. Drug Testing and Analysis, 2019, 11, 1453-1459.	1.6	2
417	Marijuana-Derived Cannabinoids Trigger a CB2/PI3K Axis of Suppression of the Innate Response to Oral Pathogens. Frontiers in Immunology, 2019, 10, 2288.	2.2	37
418	The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot Study. Integrative Cancer Therapies, 2019, 18, 153473541988149.	0.8	40
419	Newly Emerging Drugs of Abuse. Handbook of Experimental Pharmacology, 2019, 258, 463-502.	0.9	14
421	Cannabis and Psychosis Through the Lens of DSM-5. International Journal of Environmental Research and Public Health, 2019, 16, 4149.	1.2	26
422	Myorelaxant Effect of Transdermal Cannabidiol Application in Patients with TMD: A Randomized, Double-Blind Trial. Journal of Clinical Medicine, 2019, 8, 1886.	1.0	35
423	Medical Cannabis for Older Patients—Treatment Protocol and Initial Results. Journal of Clinical Medicine, 2019, 8, 1819.	1.0	26
424	Assessment of Acute Motor Effects and Tolerance Following Selfâ€Administration of Alcohol and Edible â^† ⁹ â€Tetrahydrocannabinol in Adolescent Male Mice. Alcoholism: Clinical and Experimental Research, 2019, 43, 2446-2457.	1.4	4
425	Cannabis, Decisionâ€Making, and Online Assistance Seeking. American Journal on Addictions, 2019, 28, 473-479.	1.3	3
426	Cannabinoids in the treatment of rheumatic diseases: Pros and cons. Autoimmunity Reviews, 2019, 18, 102409.	2.5	26
427	Cannabinoids-Human Physiology and Agronomic Principles for Production. Assa, Cssa and Sssa, 0, , 73-91.	0.6	5
428	Medical marijuana use for pediatric oncology patients: single institution experience. Pediatric Hematology and Oncology, 2019, 36, 255-266.	0.3	11
429	A review of bioanalytical techniques for evaluation of cannabis (Marijuana, weed, Hashish) in human hair. BMC Chemistry, 2019, 13, 106.	1.6	14
430	Dual-Purpose Materials Based on Carbon Xerogel Microspheres (CXMs) for Delayed Release of Cannabidiol (CBD) and Subsequent Aflatoxin Removal. Molecules, 2019, 24, 3398.	1.7	5
431	A randomised controlled trial of vaporised î"9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 17-35.	1.8	136

#	Article	IF	CITATIONS
432	Prospects for the Use of Cannabinoids in Oncology and Palliative Care Practice: A Review of the Evidence. Cancers, 2019, 11, 129.	1.7	26
433	Development of Standard Operating Protocols for the Optimization of Cannabis-Based Formulations for Medical Purposes. Frontiers in Pharmacology, 2019, 10, 701.	1.6	18
434	Antitumor Cannabinoid Chemotypes: Structural Insights. Frontiers in Pharmacology, 2019, 10, 621.	1.6	24
435	Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia: a systematic review. Therapeutic Advances in Drug Safety, 2019, 10, 204209861984699.	1.0	31
436	Cannabinoids, hippocampal excitability and efficacy for the treatment of epilepsy., 2019, 202, 32-39.		3
437	Multi-drug cocktails: Impurities in commonly used illicit drugs seized by police in Queensland, Australia. Drug and Alcohol Dependence, 2019, 201, 49-57.	1.6	31
438	Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model. Environmental Toxicology and Pharmacology, 2019, 70, 103202.	2.0	67
439	Marijuana and fertility. Cmaj, 2019, 191, E638-E638.	0.9	8
440	Minimal Physiologically Based Pharmacokinetic Model of Intravenously and Orally Administered Delta-9-Tetrahydrocannabinol in Healthy Volunteers. European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44, 691-711.	0.6	12
441	Fast and Sensitive Quantification of \hat{l} 'sup>9-Tetrahydrocannabinol and Its Main Oxidative Metabolites by Liquid Chromatography/Tandem Mass Spectrometry. Cannabis and Cannabinoid Research, 2019, 4, 110-123.	1.5	24
442	Cannabis use as a risk factor for causing motor vehicle crashes: a prospective study. Addiction, 2019, 114, 1616-1626.	1.7	69
443	Pharmacological evidence of medicinal cannabis in oncology: a systematic review. Supportive Care in Cancer, 2019, 27, 3195-3207.	1.0	17
444	A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics. , 2019, 201, 25-38.		65
445	Medical Cannabis Use in Glioma Patients Treated at a Comprehensive Cancer Center in Florida. Journal of Palliative Medicine, 2019, 22, 1202-1207.	0.6	26
446	Using Cannabis to Treat Cancer-Related Pain. Seminars in Oncology Nursing, 2019, 35, 300-309.	0.7	14
447	Self-administration of edible î"9-tetrahydrocannabinol and associated behavioral effects in mice. Drug and Alcohol Dependence, 2019, 199, 106-115.	1.6	21
448	Cannabinoids in Pain Treatment: An Overview. Pain Management Nursing, 2019, 20, 107-112.	0.4	8
449	Targeting Inflammatory Pathways in Alzheimer's Disease: A Focus on Natural Products and Phytomedicines. CNS Drugs, 2019, 33, 457-480.	2.7	27

#	Article	IF	Citations
450	A Review of Cannabis in Chronic Kidney Disease Symptom Management. Canadian Journal of Kidney Health and Disease, 2019, 6, 205435811982839.	0.6	31
451	Use of illicit amphetamines is associated with long-lasting changes in hand circuitry and control. Clinical Neurophysiology, 2019, 130, 655-665.	0.7	4
452	Acute Illness Associated With Cannabis Use, by Route of Exposure. Annals of Internal Medicine, 2019, 170, 531.	2.0	124
453	The effects of alcohol and cannabinoid exposure during the brain growth spurt on behavioral development in rats. Birth Defects Research, 2019, 111, 760-774.	0.8	27
454	In Vitro Inhibition of Carboxylesterase 1 by Major Cannabinoids and Selected Metabolites. Drug Metabolism and Disposition, 2019, 47, 465-472.	1.7	32
455	Altered motor development following late gestational alcohol and cannabinoid exposure in rats. Neurotoxicology and Teratology, 2019, 73, 31-41.	1.2	21
456	Cannabis and Cardiovascular Disease. Current Atherosclerosis Reports, 2019, 21, 21.	2.0	33
457	Aging circadian rhythms and cannabinoids. Neurobiology of Aging, 2019, 79, 110-118.	1.5	28
458	Detection of cannabinoids in hair after cosmetic application of hemp oil. Scientific Reports, 2019, 9, 2582.	1.6	18
459	Association of Marijuana Use with Changes in Cognitive Processing Speed and Flexibility for 17 Years in HIV-Seropositive and HIV-Seronegative Men. Substance Use and Misuse, 2019, 54, 525-537.	0.7	15
460	Potential Use of Cannabinoids for the Treatment of Pancreatic Cancer. Journal of Pancreatic Cancer, 2019, 5, 1-7.	1.6	30
461	Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination. Medicines (Basel, Switzerland), 2019, 6, 31.	0.7	112
462	Developmental Perspectives and Risk Factors for Substance Use. , 2019, , 15-24.		1
463	PHARMACOLOGY OF NOVAL CANNABINOIDS. International Journal of Pharmacy and Pharmaceutical Sciences, 2019, , 1-5.	0.3	0
464	Beyond the Bud. Pediatric Clinics of North America, 2019, 66, 1087-1097.	0.9	15
465	Caring for Patients Using Medical Marijuana. Journal of Nursing Regulation, 2019, 10, 47-61.	1.6	2
466	Extended Attenuation of Corticostriatal Power and Coherence after Acute Exposure to Vapourized Δ9-Tetrahydrocannabinol in Rats. Canadian Journal of Addiction, 2019, 10, 60-66.	0.2	9
467	Cannabidiolâ€"from Plant to Human Body: A Promising Bioactive Molecule with Multi-Target Effects in Cancer. International Journal of Molecular Sciences, 2019, 20, 5905.	1.8	81

#	Article	IF	Citations
468	Nature's Derivative(s) as Alternative Anti-Alzheimer's Disease Treatments. Journal of Alzheimer's Disease Reports, 2019, 3, 279-297.	1.2	13
469	Perfusion Index Analysis in Patients Presenting to the Emergency Department Due to Synthetic Cannabinoid Use. Medicina (Lithuania), 2019, 55, 752.	0.8	5
470	Trends in marijuana edible consumption and perceptions of harm in a cohort of young adults. Drug and Alcohol Dependence, 2019, 205, 107660.	1.6	33
471	Cannabis-based medicines for chronic pain management. Current Opinion in Anaesthesiology, 2019, 32, 623-628.	0.9	11
472	Introduction: Cannabis in Society Today. Nutrition Today, 2019, 54, 78-83.	0.6	1
473	Marijuana Use in Pregnancy: A Review. Obstetrical and Gynecological Survey, 2019, 74, 415-428.	0.2	70
474	Acute Cannabis Toxicity. Pediatric Emergency Care, 2019, 35, 799-804.	0.5	40
475	Association between cannabis use and complications related to ulcerative colitis in hospitalized patients. Medicine (United States), 2019, 98, e16551.	0.4	12
476	Perioperative Management of the Pediatric Patient on Medicinal Marijuana. Anesthesia and Analgesia, 2019, 129, 1339-1343.	1.1	11
477	Cannabinoid Hyperemesis. Medical Cannabis and Cannabinoids, 2019, 1, 73-95.	1.2	15
478	Regular cannabis use is associated with altered activation of central executive and default mode networks even after prolonged abstinence in adolescent users: Results from a complementary meta-analysis. Neuroscience and Biobehavioral Reviews, 2019, 96, 45-55.	2.9	40
479	Efficacy of cannabinoids in paediatric epilepsy. Developmental Medicine and Child Neurology, 2019, 61, 13-18.	1.1	30
480	Combined â^†9-tetrahydrocannabinol and moderate alcohol administration: effects on ingestive behaviors in adolescent male rats. Psychopharmacology, 2019, 236, 671-684.	1.5	22
481	Palmitic acid ester of tetrahydrocannabinol (THC) and palmitic acid diester of 11-hydroxy-THC â€" Unsuccessful search for additional THC metabolites in human body fluids and tissues. Forensic Science International, 2019, 294, 86-95.	1.3	7
482	Impact of recreational and medicinal marijuana on surgical patients: A review. American Journal of Surgery, 2019, 217, 783-786.	0.9	15
483	Examining links between cannabis potency and mental and physical health outcomes. Behaviour Research and Therapy, 2019, 115, 111-120.	1.6	30
484	Cannabinoid concentrations in confiscated cannabis samples and in whole blood and urine after smoking CBD-rich cannabis as a "tobacco substitute― International Journal of Legal Medicine, 2019, 133, 821-832.	1.2	29
485	Recurrent Cardiogenic Shock Associated with Cannabis Use: Report of a Case and Review of the Literature. Journal of Emergency Medicine, 2019, 56, 319-322.	0.3	10

#	Article	IF	CITATIONS
486	The neuropsychopharmacology of cannabis: A review of human imaging studies., 2019, 195, 132-161.		165
487	A 21st Century Problem: Cannabis Toxicity in a 13-Month-Old Child. Journal of Emergency Medicine, 2019, 56, 94-96.	0.3	8
488	Enhancing effects of acute exposure to cannabis smoke on working memory performance. Neurobiology of Learning and Memory, 2019, 157, 151-162.	1.0	21
489	Adolescent exposure to î"9-tetrahydrocannabinol alters the transcriptional trajectory and dendritic architecture of prefrontal pyramidal neurons. Molecular Psychiatry, 2019, 24, 588-600.	4.1	89
490	Driving and riding under the influence of recent marijuana use: Risk factors among a racially diverse sample of young adults. Journal of Ethnicity in Substance Abuse, 2019, 18, 594-612.	0.6	11
491	Results from the Colorado Cannabis Users Survey on Health (CUSH), 2016. International Journal of Mental Health and Addiction, 2020, 18, 1-13.	4.4	11
492	Disposition of oral delta-9 tetrahydrocannabinol (THC) in children receiving cannabis extracts for epilepsy. Clinical Toxicology, 2020, 58, 124-128.	0.8	9
493	Cannabis treatment in hospitalized patients using the SYQE inhaler: Results of a pilot open-label study. Palliative and Supportive Care, 2020, 18, 12-17.	0.6	12
494	Sex differences in the acute effects of smoked cannabis: evidence from a human laboratory study of young adults. Psychopharmacology, 2020, 237, 305-316.	1.5	75
495	The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: A systematic review and network meta-analysis. Journal of the American Pharmacists Association: JAPhA, 2020, 60, 225-234.e6.	0.7	43
496	Directâ€acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCVâ€infected patients. Liver International, 2020, 40, 32-44.	1.9	21
497	Short- and Long-Term Effects of Cannabis on Headache and Migraine. Journal of Pain, 2020, 21, 722-730.	0.7	39
498	Neurocognitive consequences of chronic cannabis use: a systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2020, 108, 358-369.	2.9	67
499	Prenatal drug exposure and neurodevelopmental programming of glucocorticoid signalling. Journal of Neuroendocrinology, 2020, 32, e12786.	1.2	24
500	â€~Standard THC units': a proposal to standardize dose across all cannabis products and methods of administration. Addiction, 2020, 115, 1207-1216.	1.7	129
501	Enhancing Efficacy, Performance, and Reliability of Cannabis Edibles: Insights from Lipid Bioavailability Studies. Annual Review of Food Science and Technology, 2020, 11, 45-70.	5.1	22
502	Pharmacists and the future of cannabis medicine. Journal of the American Pharmacists Association: JAPhA, 2020, 60, 207-211.	0.7	19
503	Population pharmacokinetic modeling of plasma Δ9â€ŧetrahydrocannabinol and an active and inactive metabolite following controlled smoked cannabis administration. British Journal of Clinical Pharmacology, 2020, 86, 611-619.	1.1	12

#	Article	IF	Citations
504	Cannabinoids. Journal of Clinical Gastroenterology, 2020, 54, 769-788.	1.1	1
505	Psychotic disorders hospitalizations associated with cannabis abuse or dependence: A nationwide big data analysis. International Journal of Methods in Psychiatric Research, 2020, 29, e1813.	1.1	18
506	Using Therapeutic Drug Monitoring and Pharmacovigilance to Overcome Some of the Challenges of Developing Medicinal Cannabis from Botanical Origins. Therapeutic Drug Monitoring, 2020, 42, 98-101.	1.0	3
507	Interference with the Cannabinoid Receptor CB1R Results in Miswiring of GnRH3 and AgRP1 Axons in Zebrafish Embryos. International Journal of Molecular Sciences, 2020, 21, 168.	1.8	11
508	Comparison of the Neurotoxic and Seizure-Inducing Effects of Synthetic and Endogenous Cannabinoids with Î" ⁹ -Tetrahydrocannabinol. Cannabis and Cannabinoid Research, 2020, 5, 32-41.	1,5	19
509	Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids. Pharmacology Biochemistry and Behavior, 2020, 199, 173059.	1.3	28
510	Cannabis vapor self-administration elicits sex- and dose-specific alterations in stress reactivity in rats. Neurobiology of Stress, 2020, 13, 100260.	1.9	16
511	Increasing cannabis use and importance as an environmental contaminant mixture and associated risks to exposed biota: A review. Critical Reviews in Environmental Science and Technology, 2022, 52, 203-239.	6.6	5
512	î"9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)., 2020,, 13-26.		1
513	Occupational Exposure to Secondhand Cannabis Smoke Among Law Enforcement Officers Providing Security at Outdoor Concert Events. Annals of Work Exposures and Health, 2020, 64, 705-714.	0.6	7
514	Cannabinoidomics $\hat{a} \in ``An analytical approach to understand the effect of medical Cannabis treatment on the endocannabinoid metabolome. Talanta, 2020, 219, 121336.$	2.9	25
515	Phytocannabinoids: Origins and Biosynthesis. Trends in Plant Science, 2020, 25, 985-1004.	4.3	195
516	In an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers. Psychopharmacology, 2020, 237, 3097-3107.	1,5	7
517	Cannabis: are there any benefits?. Internal Medicine Journal, 2020, 50, 1326-1332.	0.5	9
518	Investigating cannabis use and associated symptoms among university students with and without a history of concussion. Neuropsychological Rehabilitation, 2020, , 1-25.	1.0	5
519	Detectability of the Psychotropic Substance Cannabis in Head or Body Hair: Update of Forensic Criminalistics. , 2020, , .		0
520	Natural Salicylates and Their Roles in Human Health. International Journal of Molecular Sciences, 2020, 21, 9049.	1.8	20
521	Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease. Molecules, 2020, 25, 5186.	1.7	45

#	Article	IF	CITATIONS
522	hiPSC-Based Model of Prenatal Exposure to Cannabinoids: Effect on Neuronal Differentiation. Frontiers in Molecular Neuroscience, 2020, 13, 119.	1.4	14
523	Medical Marijuana, Recreational Cannabis, and Cardiovascular Health: A Scientific Statement From the American Heart Association. Circulation, 2020, 142, e131-e152.	1.6	115
524	Cannabis health knowledge and risk perceptions among Canadian youth and young adults. Harm Reduction Journal, 2020, 17, 54.	1.3	22
525	The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations. Clinical Pharmacokinetics, 2020, 59, 1493-1500.	1.6	31
526	Application of Cannabinoids in Neurosciences. Critical Care Nursing Quarterly, 2020, 43, 216-231.	0.4	0
527	Anesthetic considerations in medical cannabis patients. Current Opinion in Anaesthesiology, 2020, 33, 832-840.	0.9	11
528	Long-Term Low-Dose Delta-9-Tetrahydrocannbinol (THC) Administration to Simian Immunodeficiency Virus (SIV) Infected Rhesus Macaques Stimulates the Release of Bioactive Blood Extracellular Vesicles (EVs) that Induce Divergent Structural Adaptations and Signaling Cues. Cells, 2020, 9, 2243.	1.8	3
529	A Large-Scale Naturalistic Examination of the Acute Effects of Cannabis on Pain. Cannabis and Cannabinoid Research, 2022, 7, 93-99.	1.5	10
530	Cannabis Legalization and Acute Harm From High Potency Cannabis Products: A Narrative Review and Recommendations for Public Health. Frontiers in Psychiatry, 2020, 11, 591979.	1.3	43
531	Pupillary effects in habitual cannabis consumers quantified with pupillography. Forensic Science International, 2020, 317, 110559.	1.3	3
532	Cannabinoids-based Medicine Pharmacology, Drug Interactions, and Perioperative Management of Surgical Patients. Advances in Anesthesia, 2020, 38, 167-188.	0.5	2
533	Cannabinoids affect the mouse visual acuity via the cannabinoid receptor type 2. Scientific Reports, 2020, 10, 15819.	1.6	11
534	Effects of \hat{a}^{\dagger} 9-tetrahydrocannabinol on aversive memories and anxiety: a review from human studies. BMC Psychiatry, 2020, 20, 420.	1.1	23
535	Medical marijuana certification for patients with sickle cell disease: a report of a single center experience. Blood Advances, 2020, 4, 3814-3821.	2.5	7
536	Effects of Smoking Cannabis on Visual Function and Driving Performance. A Driving-Simulator Based Study. International Journal of Environmental Research and Public Health, 2020, 17, 9033.	1.2	15
537	Illicit Cannabis Usage as a Management Strategy in New Zealand Women with Endometriosis: An Online Survey. Journal of Women's Health, 2021, 30, 1485-1492.	1.5	18
538	Is the Urine Cannabinoid Level Measured via a Commercial Point-of-Care Semiquantitative Immunoassay a Cannabis Withdrawal Syndrome Severity Predictor?. Frontiers in Psychiatry, 2020, 11, 598150.	1.3	6
540	Cannabinoids in Glaucoma Patients: The Never-Ending Story. Journal of Clinical Medicine, 2020, 9, 3978.	1.0	21

#	Article	IF	CITATIONS
541	Secondhand Marijuana: Prenatal Cannabis Exposure., 2020,, 125-136.		0
542	Lower-Risk Cannabis Use Guidelines: Adherence in Canada and the U.S American Journal of Preventive Medicine, 2020, 59, e211-e220.	1.6	9
543	The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. Drug and Alcohol Dependence, 2020, 212, 107993.	1.6	49
544	Herbal Preparations of Medical Cannabis: A Vademecum for Prescribing Doctors. Medicina (Lithuania), 2020, 56, 237.	0.8	51
545	THC Exposure is Reflected in the Microstructure of the Cerebral Cortex and Amygdala of Young Adults. Cerebral Cortex, 2020, 30, 4949-4963.	1.6	7
546	Acute neuroradiological, behavioral, and physiological effects of nose-only exposure to vaporized cannabis in C57BL/6 mice. Inhalation Toxicology, 2020, 32, 200-217.	0.8	19
547	Cannabis, e-cigarettes and anesthesia. Current Opinion in Anaesthesiology, 2020, 33, 318-326.	0.9	14
548	Cannabis and multiple sclerosis. Expert Review of Neurotherapeutics, 2020, 20, 849-854.	1.4	22
549	Precipitated î"9-THC withdrawal reduces motivation for sucrose reinforcement in mice. Pharmacology Biochemistry and Behavior, 2020, 195, 172966.	1.3	3
550	THC and CBD blood and brain concentrations following daily administration to adolescent primates. Drug and Alcohol Dependence, 2020, 213, 108129.	1.6	14
551	Experiences with medical cannabis in the treatment of veterans with PTSD: Results from a focus group discussion. European Neuropsychopharmacology, 2020, 36, 244-254.	0.3	25
552	Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. CNS Drugs, 2020, 34, 795-800.	2.7	81
553	Prenatal Risk Factors and Neurodevelopment. , 2020, , 608-620.		3
554	Cannabinoids, Blood–Brain Barrier, and Brain Disposition. Pharmaceutics, 2020, 12, 265.	2.0	67
555	The relationship of cannabis decriminalization in Colorado and cannabis use in individuals with alcohol use disorders. Journal of Cannabis Research, 2020, 2, 13.	1.5	2
556	Lifetime Average Cannabis Use in Relation to Hypertriglyceridemic Waist Phenotype in U.S. Adults: A Population-Based Cross-Sectional Study. Cannabis and Cannabinoid Research, 2020, 5, 246-254.	1.5	4
557	Cautious Hope for Cannabidiol (<scp>CBD</scp>) in Rheumatology Care. Arthritis Care and Research, 2023, 75, 1371-1375.	1.5	22
558	Cannabinoids in the Management of Acute Pain: A Systematic Review and Meta-analysis. Cannabis and Cannabinoid Research, 2020, 5, 290-297.	1.5	26

#	Article	IF	CITATIONS
559	Cannabis increases susceptibility to false memory. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4585-4589.	3.3	21
560	What the lab can and cannot do: clinical interpretation of drug testing results. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 548-585.	2.7	18
561	Phytocannabinoid drug-drug interactions and their clinical implications., 2020, 215, 107621.		15
562	Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. Drug Metabolism and Disposition, 2020, 48, 1008-1017.	1.7	50
563	Synthesis of the Major Mammalian Metabolites of THCV. Journal of Natural Products, 2020, 83, 2060-2065.	1.5	1
564	"Residual blood THC levels in frequent cannabis users after over four hours of abstinence: A systematic review.― Drug and Alcohol Dependence, 2020, 216, 108177.	1.6	14
565	Neuroprotection Following Concussion: The Potential Role for Cannabidiol. Canadian Journal of Neurological Sciences, 2020, 47, 289-300.	0.3	13
566	Cannabinoids in the Pathophysiology of Skin Inflammation. Molecules, 2020, 25, 652.	1.7	60
567	Cannabinoids in the Treatment of Back Pain. Neurosurgery, 2020, 87, 166-175.	0.6	14
568	Vaporized Cannabis Extracts Have Reinforcing Properties and Support Conditioned Drug-Seeking Behavior in Rats. Journal of Neuroscience, 2020, 40, 1897-1908.	1.7	83
569	Electrochemical Sensing of Cannabinoids in Biofluids: A Noninvasive Tool for Drug Detection. ACS Sensors, 2020, 5, 620-636.	4.0	50
570	Δ9-tetrahydrocannabinol (THC) is present in the body between smoking sessions in occasional non-daily cannabis users. Forensic Science International, 2020, 309, 110188.	1.3	10
571	Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study. Translational Psychiatry, 2020, 10, 71.	2.4	48
572	Substance Use Disorders in Vulnerable Children. Pediatric Clinics of North America, 2020, 67, 373-385.	0.9	O
573	Is cannabidiol a scheduled controlled substance? Origin makes the difference. Drug Discovery Today, 2020, 25, 628-632.	3.2	5
574	Risk of Persistence and Progression of Use of 5 Cannabis Products After Experimentation Among Adolescents. JAMA Network Open, 2020, 3, e1919792.	2.8	22
575	Spectroelectrochemical and computational studies of tetrahydrocannabinol (THC) and carboxy-tetrahydrocannabinol (THC-COOH). Analyst, The, 2020, 145, 1849-1857.	1.7	25
576	Development of a Physiologically-Based Pharmacokinetic Model of Δ9-Tetrahydrocannabinol in Mice, Rats, and Pigs. European Journal of Drug Metabolism and Pharmacokinetics, 2020, 45, 487-494.	0.6	9

#	Article	IF	CITATIONS
577	A î"9-Tetrahydrocannabinol Physiologically-Based Pharmacokinetic Model Development in Humans. European Journal of Drug Metabolism and Pharmacokinetics, 2020, 45, 495-511.	0.6	8
578	Prolonged oral transmucosal delivery of highly lipophilic drug cannabidiol. International Journal of Pharmaceutics, 2020, 581, 119276.	2.6	29
579	MyD88-dependent and -independent signalling via TLR3 and TLR4 are differentially modulated by Δ9-tetrahydrocannabinol and cannabidiol in human macrophages. Journal of Neuroimmunology, 2020, 343, 577217.	1.1	34
580	Cannabinoids as anticancer therapeutic agents. Cell Cycle, 2020, 19, 961-989.	1.3	61
581	A Systematic Review of the Effects of Perinatal Alcohol Exposure and Perinatal Marijuana Exposure on Adult Neurogenesis in the Dentate Gyrus. Alcoholism: Clinical and Experimental Research, 2020, 44, 1164-1174.	1.4	11
582	Cannabinoids and psychotic symptoms: A potential role for a genetic variant in the P2X purinoceptor 7 (P2RX7) gene. Brain, Behavior, and Immunity, 2020, 88, 573-581.	2.0	14
583	Impact of 2 Weeks of Monitored Abstinence on Cognition in Adolescent and Young Adult Cannabis Users. Journal of the International Neuropsychological Society, 2020, 26, 776-784.	1.2	23
584	Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol. Pharmacological Research, 2020, 157, 104822.	3.1	75
585	Prenatal tobacco and marijuana co-use: Sex-specific influences on infant cortisol stress response. Neurotoxicology and Teratology, 2020, 79, 106882.	1.2	9
586	Characterizing the predictive validity of measures of susceptibility to future use of combustible, vaporized and edible cannabis products in adolescent neverâ€users. Addiction, 2020, 115, 2339-2348.	1.7	8
587	Youth marijuana use: a review of causes and consequences. Current Opinion in Psychology, 2021, 38, 11-18.	2.5	28
588	Emerging potential of cannabidiol in reversing proteinopathies. Ageing Research Reviews, 2021, 65, 101209.	5.0	28
589	Acute effects of partial CB1 receptor agonists on cognition – A meta-analysis of human studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110063.	2.5	19
590	Cannabinoids and the eye. Survey of Ophthalmology, 2021, 66, 327-345.	1.7	21
591	Acute Effects of Cannabis on Symptoms of Obsessive-Compulsive Disorder. Journal of Affective Disorders, 2021, 279, 158-163.	2.0	8
592	A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as singleâ€dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers. British Journal of Clinical Pharmacology, 2021, 87, 2070-2077.	1.1	21
593	Sex, species and age: Effects of rodent demographics on the pharmacology of â^†9-tetrahydrocanabinol. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 106, 110064.	2.5	31
594	Patterns and correlates of workplace and non-workplace cannabis use among Canadian workers before the legalization of non-medical cannabis. Drug and Alcohol Dependence, 2021, 218, 108386.	1.6	5

#	Article	IF	CITATIONS
595	The endocannabinoid system – current implications for drug development. Journal of Internal Medicine, 2021, 290, 2-26.	2.7	21
596	Cannabis is associated with blood pressure reduction in older adults – A 24-hours ambulatory blood pressure monitoring study. European Journal of Internal Medicine, 2021, 86, 79-85.	1.0	17
597	Nephrologist Views Regarding Cannabinoid Use in Advanced Chronic Kidney Disease and Dialysis: A Survey. Journal of Pain and Symptom Management, 2021, 61, 237-245.e2.	0.6	5
598	Ordering in alcohol and cannabis co-use: Impact on daily consumption and consequences. Drug and Alcohol Dependence, 2021, 218, 108339.	1.6	22
599	Communicating THC levels and †dose†to consumers: Implications for product labelling and packaging of cannabis products in regulated markets. International Journal of Drug Policy, 2021, 91, 102509.	1.6	59
600	Disrupted parahippocampal and midbrain function underlie slower verbal learning in adolescent-onset regular cannabis use. Psychopharmacology, 2021, 238, 1315-1331.	1.5	16
601	Clinical Evidence of Magistral Preparations Based on Medicinal Cannabis. Pharmaceuticals, 2021, 14, 78.	1.7	6
602	Cannabis use and measurement of cannabinoids in plasma and breast milk of breastfeeding mothers. Pediatric Research, 2021, 90, 861-868.	1.1	29
603	Effect of prenatal marijuana exposure on sleep wake cycles and amplitude-integrated electroencephalogram (aEEG). Journal of Perinatology, 2021, 41, 1355-1363.	0.9	6
604	Development of Stimuli-Responsive Chitosan/ZnO NPs Transdermal Systems for Controlled Cannabidiol Delivery. Polymers, 2021, 13, 211.	2.0	12
605	Psychopharmacology of Drugs of Abuse. , 2021, , 3-21.		0
606	Cannabinoids and Herbal Medicine. , 2021, , 249-254.		0
607	The Chemistry of Cannabis and Cannabinoids. Australian Journal of Chemistry, 2021, 74, 369-387.	0.5	17
608	Pre-sedation Assessment. , 2021, , 49-82.		1
609	Cannabinoids and Child Development: During and After Pregnancy., 2021,, 287-290.		0
610	Effects of cannabis on visual function and self-perceived visual quality. Scientific Reports, 2021, 11, 1655.	1.6	16
611	The Management of Cancer Symptoms and Treatment-Induced Side Effects With Cannabis or Cannabinoids. Journal of the National Cancer Institute Monographs, 2021, 2021, 86-98.	0.9	17
612	Medical Cannabis in Oncology: a Valuable Unappreciated Remedy or an Undesirable Risk?. Current Treatment Options in Oncology, 2021, 22, 16.	1.3	15

#	Article	IF	CITATIONS
613	Phytocannabinoids: Tetrahydrocannabinol (THC)., 2021,, 71-77.		3
615	Medicinal Cannabis: an overview for health-care providers. , 2021, , 75-101.		4
616	Cannabis thérapeutique : l'expérience canadienne. Douleur Et Analgesie, 2021, 34, 179-187.	0.2	0
617	Clinical Pharmacokinetics of Cannabinoids and Potential Drug-Drug Interactions. Advances in Experimental Medicine and Biology, 2021, 1297, 27-42.	0.8	8
618	A Multiple Correspondence Analysis of Patterns of CBD Use in Hemp and Marijuana Users. Frontiers in Psychiatry, 2020, 11 , 624012.	1.3	6
619	Pipette tip microâ€solid phase extraction (octylâ€functionalized hybrid silica monolith) and ultraâ€highâ€performance liquid chromatographyâ€tandem mass spectrometry to determine cannabidiol and tetrahydrocannabinol in plasma samples. Journal of Separation Science, 2021, 44, 1621-1632.	1.3	9
621	The emergency department care of the cannabis and synthetic cannabinoid patient: a narrative review. International Journal of Emergency Medicine, 2021, 14, 10.	0.6	10
622	Cannabis and Cannabis Edibles: A Review. Journal of Agricultural and Food Chemistry, 2021, 69, 1751-1774.	2.4	39
623	Cannabis-Based Oral Formulations for Medical Purposes: Preparation, Quality and Stability. Pharmaceuticals, 2021, 14, 171.	1.7	9
624	Measurement of the adult human midbrain with transcranial ultrasound. PLoS ONE, 2021, 16, e0247920.	1.1	5
625	The Effects of Cannabis: Implications for the Surgical Patient. Plastic and Reconstructive Surgery - Global Open, 2021, 9, e3448.	0.3	6
626	A Systematic Study of the In Vitro Pharmacokinetics and Estimated Human In Vivo Clearance of Indole and Indazole-3-Carboxamide Synthetic Cannabinoid Receptor Agonists Detected on the Illicit Drug Market. Molecules, 2021, 26, 1396.	1.7	15
627	Acute effects of cannabis consumption on exercise performance: a systematic and umbrella review. Journal of Sports Medicine and Physical Fitness, 2021, 61, 551-561.	0.4	4
628	Duration of Neurocognitive Impairment With Medical Cannabis Use: A Scoping Review. Frontiers in Psychiatry, 2021, 12, 638962.	1.3	21
629	Electrochemical sensing: A prognostic tool in the fight against COVID-19. TrAC - Trends in Analytical Chemistry, 2021, 136, 116198.	5.8	40
631	An Agathokakological Tale of î"9-THC: Exploration of Possible Biological Targets. Current Drug Targets, 2021, 22, 823-834.	1.0	3
632	Aggressive Driving Behaviours in Cannabis Users. The Influence of Consumer Characteristics. International Journal of Environmental Research and Public Health, 2021, 18, 3911.	1.2	4
633	Exo- and Endo-cannabinoids in Depressive and Suicidal Behaviors. Frontiers in Psychiatry, 2021, 12, 636228.	1.3	8

#	Article	IF	CITATIONS
634	Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review. Psychiatric Services, 2021, 72, 429-436.	1.1	45
635	Practical Strategies Using Medical Cannabis to Reduce Harms Associated With Long Term Opioid Use in Chronic Pain. Frontiers in Pharmacology, 2021, 12, 633168.	1.6	20
636	Cognitive performance and lifetime cannabis use in patients with first-episode schizophrenia spectrum disorder. Cognitive Neuropsychiatry, 2021, 26, 257-272.	0.7	6
638	Cannabinoids and Pain. Rheumatic Disease Clinics of North America, 2021, 47, 265-275.	0.8	1
639	Sensory gating in tobacco-na \tilde{A} -ve cannabis users is unaffected by acute nicotine administration. Psychopharmacology, 2022, 239, 1279-1288.	1.5	1
640	Medicinal Applications of Cannabinoids Extracted from Cannabis sativa (L.): A New Route in the Fight Against COVID-19?. Current Pharmaceutical Design, 2021, 27, 1564-1578.	0.9	11
641	Cannabis use, abuse, and withdrawal: Cannabinergic mechanisms, clinical, and preclinical findings. Journal of Neurochemistry, 2021, 157, 1674-1696.	2.1	27
642	Effect of preoperative cannabis use on perioperative outcomes: a retrospective cohort study. Regional Anesthesia and Pain Medicine, 2021, 46, 650-655.	1.1	12
643	Enhancing the Cannabidiol (CBD) Compound in Formulated Hemp (Cannabis sativa L.) Leaves through the Application of Hot-Melt Extrusion. Processes, 2021, 9, 837.	1.3	4
644	The why behind the high: determinants of neurocognition during acute cannabis exposure. Nature Reviews Neuroscience, 2021, 22, 439-454.	4.9	36
645	Inflammatory Bowel Disease and Cannabis: A Practical Approach for Clinicians. Advances in Therapy, 2021, 38, 4152-4161.	1.3	4
646	The Impact of Marijuana on Antidepressant Treatment in Adolescents: Clinical and Pharmacologic Considerations. Journal of Personalized Medicine, 2021, 11, 615.	1.1	16
647	Delivering therapeutic cannabinoids via skin: Current state and future perspectives. Journal of Controlled Release, 2021, 334, 427-451.	4.8	35
648	Cannabidiol-Driven Alterations to Inflammatory Protein Landscape of Lipopolysaccharide-Activated Macrophages <i>In Vitro</i> May Be Mediated by Autophagy and Oxidative Stress. Cannabis and Cannabinoid Research, 2021, 6, 253-263.	1.5	21
649	Pharmacokinetics and Perceptions of Children and Young Adults Using Cannabis for Attention-Deficit/Hyperactivity Disorder and Oppositional Defiant Disorder: Protocol for a Mixed Methods Proof-Of-Concept Study. JMIR Research Protocols, 2021, 10, e31281.	0.5	3
651	Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. Journal of Cannabis Research, 2021, 3, 22.	1.5	68
652	Efficacy of cannabinoids against glioblastoma multiforme: A systematic review. Phytomedicine, 2021, 88, 153533.	2.3	8
653	Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?. Pharmacology Biochemistry and Behavior, 2021, 206, 173192.	1.3	9

#	Article	IF	CITATIONS
654	Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2). Drug Metabolism and Disposition, 2021, 49, 910-918.	1.7	6
656	Influence of Cannabinoid Receptor 1 Genetic Variants on the Subjective Effects of Smoked Cannabis. International Journal of Molecular Sciences, 2021, 22, 7388.	1.8	6
657	Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?. F1000Research, 2019, 8, 1394.	0.8	26
658	Curcumin, Resveratrol and Cannabidiol as Natural Key Prototypes in Drug Design for Neuroprotective Agents. Current Neuropharmacology, 2022, 20, 1297-1328.	1.4	2
659	Form and content of Jamaican cannabis edibles. Journal of Cannabis Research, 2021, 3, 29.	1.5	4
660	Adolescent cannabinoid exposure modulates the vulnerability to cocaine-induced conditioned place preference and DNMT3a expression in the prefrontal cortex in Swiss mice. Psychopharmacology, 2021, 238, 3107-3118.	1.5	3
662	Dynamics of the accommodative response after smoking cannabis. Ophthalmic and Physiological Optics, 2021, 41, 1097-1109.	1.0	6
663	A comparative analysis of laws on recreational cannabis edibles between Canada and the United States of America. International Journal of Drug Policy, 2021, 94, 103191.	1.6	6
664	A pilot safety, tolerability and pharmacokinetic study of an oro-buccal administered cannabidiol-dominant anti-inflammatory formulation in healthy individuals: a randomized placebo-controlled single-blinded study. Inflammopharmacology, 2021, 29, 1361-1370.	1.9	9
665	Cannabis and Athletic Performance. Sports Medicine, 2021, 51, 75-87.	3.1	8
666	Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain. Drugs, 2021, 81, 1513-1557.	4.9	44
667	Endocannabinoids, cannabinoids and the regulation of anxiety. Neuropharmacology, 2021, 195, 108626.	2.0	34
668	Synthesis, characterization and stress-testing of a robust quillaja saponin stabilized oil-in-water phytocannabinoid nanoemulsion. Journal of Cannabis Research, 2021, 3, 43.	1.5	11
669	Analysis of toxicity effects of delta-9-tetrahydrocannabinol on isolated rat heart mitochondria. Toxicology Mechanisms and Methods, 2022, 32, 106-113.	1.3	3
670	Glaucoma Clinical Research: Trends in Treatment Strategies and Drug Development. Frontiers in Medicine, 2021, 8, 733080.	1.2	33
671	The growing dilemma of legalized cannabis and heart transplantation. Journal of Heart and Lung Transplantation, 2021, 40, 863-871.	0.3	7
672	Cannabis and mental health: Prevalence of use and modes of cannabis administration by mental health status. Addictive Behaviors, 2021, 121, 106991.	1.7	18
673	A review of the effects of acute and chronic cannabinoid exposure on the stress response. Frontiers in Neuroendocrinology, 2021, 63, 100945.	2.5	6

#	Article	IF	CITATIONS
674	Adults with a history of recreational cannabis use have altered speech production. Drug and Alcohol Dependence, 2021, 227, 108963.	1.6	3
675	The link between neurology and behavior in veterinary medicine: A review. Journal of Veterinary Behavior: Clinical Applications and Research, 2021, 46, 40-53.	0.5	3
676	Assessing methamphetamine-related cue reactivity in people with methamphetamine use disorder relative to controls. Addictive Behaviors, 2021, 123, 107075.	1.7	12
677	Delta-9-tetrahydrocannabinol (\hat{l} " ⁹ -THC) sensing using an aerosol jet printed organic electrochemical transistor (OECT). Journal of Materials Chemistry B, 2021, 9, 2107-2117.	2.9	17
678	Cannabis Withdrawal., 2021,, 317-322.		0
679	Other Phytocannabinoids. , 2021, , 87-92.		1
680	Dronabinol (Marinol®)., 2021,, 105-107.		2
681	Population pharmacokinetic model of blood THC and its metabolites in chronic and occasional cannabis users and relationship with onâ€site oral fluid testing. British Journal of Clinical Pharmacology, 2021, 87, 3139-3149.	1.1	9
682	Therapeutic potential of cannabinoids in combination cancer therapy. Advances in Biological Regulation, 2021, 79, 100774.	1.4	21
683	Potential use of cannabimimetics in the treatment of cancer. , 2005, , 165-181.		2
685	Cannabinoids. , 2014, , 487-510.		1
686	Human Cannabinoid Pharmacokinetics and Interpretation of Cannabinoid Concentrations in Biological Fluids and Tissues., 2007,, 205-235.		5
687	Pharmacokinetics and pharmacodynamics of drugs abused in driving., 2009,, 151-185.		2
688	Clinical Toxicology. , 2012, , 1109-1188.		2
689	Determination of cannabinoids in cannabis products using liquid chromatography–ion trap mass spectrometry. Journal of Chromatography A, 2004, 1058, 143-151.	1.8	12
690	Stability characteristics of cannabidiol for the design of pharmacological, biochemical and pharmaceutical studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1150, 122188.	1.2	37
691	Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncology, The, 2005, 6, 35-42.	5.1	74
693	Subjective cannabis effects as part of a developing disorder in adolescents and emerging adults Journal of Abnormal Psychology, 2018, 127, 282-293.	2.0	20

#	Article	IF	CITATIONS
694	Consommation de cannabis: quels sont les risquesÂ?. Toxicologie Analytique Et Clinique, 2008, 20, 183-205.	0.1	8
695	Analyse des cannabino \tilde{A}^- des par spectrom \tilde{A} ©trie de masse en mode tandem. Toxicologie Analytique Et Clinique, 2011, 23, 21-35.	0.1	1
696	The effect of oral \hat{l} "-9-tetrahydrocannabinol on the minimal alveolar concentration of sevoflurane. European Journal of Anaesthesiology, 2021, 38, 58-63.	0.7	5
697	Translational models of cannabinoid vapor exposure in laboratory animals. Behavioural Pharmacology, 2020, Publish Ahead of Print, .	0.8	21
700	Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?. F1000Research, 0, 8, 1394.	0.8	30
701	Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?. F1000Research, 2019, 8, 1394.	0.8	28
702	Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?. F1000Research, 0, 8, 1394.	0.8	25
703	Marijuana Use and Potential Implications of Marijuana Legalization. Pediatrics in Review, 2020, 41, 61-72.	0.2	15
704	TAXING THE POTENCY OF SIN GOODS. National Tax Journal, 2020, 73, 511-544.	0.4	19
705	Mandatory pharmacist-led education session for patients seeking medical cannabis. Pharmacy Practice, 2020, 18, 2088.	0.8	4
706	Acute and Non-acute Effects of Cannabis on Human Memory Function: A Critical Review of Neuroimaging Studies. Current Pharmaceutical Design, 2014, 20, 2114-2125.	0.9	68
707	Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System. CNS and Neurological Disorders - Drug Targets, 2012, 11, 624-641.	0.8	32
708	Cannabinoid Hyperemesis Syndrome. Current Drug Abuse Reviews, 2011, 4, 241-249.	3.4	239
709	The Protective Mechanism of Cannabidiol in Cardiac Injury: A Systematic Review of Non-Clinical Studies. Current Pharmaceutical Design, 2019, 25, 2499-2507.	0.9	25
710	Navigating Blind in the Green Rush: Clinical Considerations and Harm Reduction Practices for Cannabis. Current Drug Research Reviews, 2019, 11, 3-11.	0.7	9
711	Marijuana Use Episodes and Partner Intimacy Experiences: A Daily Report Study., 2019, 2, 19-28.		6
712	Nanocomposite Cryogel Carriers from 2-Hydroxyethyl Cellulose Network and Cannabidiol-Loaded Polymeric Micelles for Sustained Topical Delivery. Polymers, 2020, 12, 1172.	2.0	19
713	Update on Marijuana. Journal of Psychosocial Nursing and Mental Health Services, 2009, 47, 19-22.	0.3	13

#	ARTICLE	IF	CITATIONS
714	Acute Marijuana Intoxication in Children. Pediatric Annals, 2018, 47, e474-e476.	0.3	5
717	Nabilone for the Treatment of Dementia-Associated Sexual Disinhibition. primary care companion for CNS disorders, The, 2015, 17, .	0.2	6
718	Functional role of cannabinoid receptors in urinary bladder. Indian Journal of Urology, 2010, 26, 26.	0.2	22
719	Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using & t;i>Cannabis& t;/i> Extract Enriched in Cannabidiol. Pharmacology & Pharmacy, 2015, 06, 75-85.	0.2	105
721	Cannabis Vaping: Existing and Emerging Modalities, Chemistry, and Pulmonary Toxicology. Chemical Research in Toxicology, 2021, 34, 2169-2179.	1.7	24
722	Biological activity of Cannabis compounds: a modern approach to the therapy of multiple diseases. Phytochemistry Reviews, 2022, 21, 429-470.	3.1	6
723	î"9-Tetrahydrocannabinol inhibits Hedgehog-dependent patterning during development. Development (Cambridge), 2021, 148, .	1.2	7
724	Self-Regulation of Driving Behavior Under the Influence of Cannabis: The Role of Driving Complexity and Driver Vision. Human Factors, 2021, , 001872082110477.	2.1	4
725	Cannabinoid tetrad effects of oral î"9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations. Psychopharmacology, 2022, 239, 1397-1408.	1.5	25
726	Medical Cannabis Use and Pain: An Experience Sampling Study. Frontiers in Psychiatry, 2021, 12, 728283.	1.3	0
727	Cannabis Dopaminergic Effects Induce Hallucinations in a Patient with Parkinson's Disease. Medicina (Lithuania), 2021, 57, 1107.	0.8	3
728	Comparison of CBD and Cannabis Use Motives. Cannabis (Research Society on Marijuana), 2021, 4, 60-68.	0.3	0
729	Cannabinoids in the Treatment of Epilepsy: A Review. European Medical Journal (Chelmsford, England), 0, , .	3.0	1
730	KomplementÃre Therapieverfahren. , 2006, , 173-369.		0
732	Pharmacokinetics of Specific Drugs., 2007,, 25-63.		4
734	Antiemetic Drugs. , 2009, , 785-796.		1
735	Addictions et grossesse., 2009,, 22-26.		0
736	Cannabinoids cases in polish athletes. Biology of Sport, 2009, 26, 119-135.	1.7	1

#	Article	IF	Citations
741	The Endocannabinoid System: A Dynamic Signalling System at the Crossroads Between Metabolism and Disease. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 155-187.	0.2	1
744	Zentrales Nervensystem. , 2015, , 229-415.		O
745	Cannabinoid Receptor Agonists. , 2016, , 1-8.		0
746	Phytocannabinoide., 2016,, 1-12.		0
748	Cannabis Chemistry: Cannabinoids in Cannabis, Humans, and Other Species., 2016, , 229-252.		0
749	Synthetic Cannabinoid Receptor Agonists. , 2017, , 1609-1616.		0
750	Phytocannabinoide., 2018,, 659-667.		0
751	Abuse of Cannabinoids. Ankara Medical Journal, 0, , .	0.1	0
752	Zentrales Nervensystem., 2018,, 253-445.		0
753	Multi-laboratory validation of a \hat{i} 9-tetrahydrocannabinol LC-MS/MS test kit designed for quantifying THC and marijuana metabolites in blood. Forensic Science and Criminology, 2018, 3, .	0.3	0
754	Alcohol and Marijuana use in Undergraduate Males: Between- and Within-Person Associations with Interpersonal Conflict. Cannabis (Research Society on Marijuana), 2018, 1, 48-59.	0.3	6
755	Arzneimitteltherapiesicherheit: Das Interaktionspotenzial der Cannabinoide. Deutsches Ärzteblatt International, 0, , .	0.6	2
757	Cannabis: Innovation Opportunities for its Medical Use. Recent Patents on Engineering, 2019, 13, 212-223.	0.3	2
758	Cannabinoids. , 2020, , 169-176.		1
759	Neurotransmitters and Their Receptors—State of the Art. , 2020, , 1-29.		0
760	Legal Use of Marijuana: Will Scientific Evidence Overwhelm Self-Perceived High Feeling?. Science Insights, 2020, 32, 133-137.	0.1	1
761	Chapter 3: Prohibited Substances and Their Actions. , 2020, , .		0
762	Accidental Acute Cannabis Intoxication Presenting as Seizure in Pediatrics Patients. Kansas Journal of Medicine, 2020, 13, 129-130.	0.1	4

#	ARTICLE	IF	CITATIONS
763	Medicinal and Recreational Marijuana. Plastic and Reconstructive Surgery - Global Open, 2020, Publish Ahead of Print, e2838.	0.3	3
764	A comprehensive approach to pain management in palliative care. MedicÃna Pro Praxi, 2020, 17, 88-92.	0.0	0
770	Routes of Administration, Pharmacokinetics and Safety of Medicinal Cannabis., 2021, , 513-557.		2
771	Cannabinoids. , 2022, , 439-456.		O
772	The effects of synthetic cannabinoids on the cardiovascular system: A case–control study. Turkish Journal of Emergency Medicine, 2021, 21, 198.	0.3	3
774	Cannabinoids as Promising Anti-inflammatory Agent. , 2020, , 93-103.		0
775	Mechanisms of Action and Pharmacokinetics of Cannabis., 2021, 25, 1-3.		32
776	Medicinal cannabis: Pharmaceutical forms and recent analytical methodologies. Comprehensive Analytical Chemistry, 2020, , 31-63.	0.7	1
777	The Pharmacodynamics, Pharmacokinetics, and Potential Drug Interactions of Cannabinoids. , 2020, , 49-61.		3
778	The Safety of Cannabis Use in Pregnancy. Open Journal of Obstetrics and Gynecology, 2021, 11, 1437-1445.	0.1	1
780	Introduction of Gamma-Aminobutyric Acid into the Bloodstream to Negate NMDA Receptor Hypofunction Induced by Delta 9-Tetrahydrocannabinol., 2020, 4, 1-7.		0
781	Marijuana and alcohol increase crash avoidance reaction time in a driving simulator test at blood concentrations below commonly-used per se  Cut-offs' for Intoxication. Journal of Addiction Medicine and Therapeutic Science, 2020, 6, 009-015.	0.3	2
783	Cannabinoidsâ€"Characteristics and Potential for Use in Food Production. Molecules, 2021, 26, 6723.	1.7	23
784	Depressionen bei AbhÃngigkeitserkrankungen. , 2005, , 91-104.		1
785	Postmortem Considerations., 2007,, 295-301.		0
800	Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iranian Journal of Psychiatry, 2012, 7, 149-56.	0.4	168
802	WHY NOT POT?: A Review of the Brain-based Risks of Cannabis. Innovations in Clinical Neuroscience, 2016, 13, 13-22.	0.1	4
803	Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. American Journal of Translational Research (discontinued), 2016, 8, 3448-59.	0.0	47

#	Article	IF	CITATIONS
804	Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting. P and T, 2017, 42, 180-188.	1.0	123
805	Regulatory and Legislative Disparities With Cannabis Present Challenges to P&T Committees and Health Care Providers. P and T, 2019, 44, 290-293.	1.0	2
806	Accidental Acute Cannabis Intoxication Presenting as Seizure in Pediatrics Patients. Kansas Journal of Medicine, 2020, 13, 129-130.	0.1	3
807	The Effectiveness of Flower for Immediate Relief from Symptoms of Depression. Yale Journal of Biology and Medicine, 2020, 93, 251-264.	0.2	4
808	Clinical Approaches to Cannabis. Medical Clinics of North America, 2022, 106, 131-152.	1.1	5
809	DART-HRMS as a triage approach for the rapid analysis of cannabinoid-infused edible matrices, personal-care products and Cannabis sativa hemp plant material. Forensic Chemistry, 2022, 27, 100382.	1.7	10
810	Marijuana toxicosis in dogs in Melbourne , Australia, following suspected ingestion of human faeces: 15 cases (2011–2020). Australian Veterinary Journal, 2021, , .	0.5	1
811	Sedation and Acute Encephalopathy in a Pediatric Patient Following Ingestion of Delta-8-Tetrahydrocannabinol Gummies. American Journal of Case Reports, 2021, 22, e933488.	0.3	18
812	Description of a Collaborative, Fee-for-service, Office-based, Pharmacist-directed Medical Cannabis Therapy Management Service for Patients with Chronic Pain. Journal of the American Pharmacists Association: JAPhA, 2021, , .	0.7	0
813	Objective Identification of Cannabis Use Levels in Clinical Populations Is Critical for Detecting Pharmacological Outcomes. Cannabis and Cannabinoid Research, 2022, 7, 852-864.	1.5	4
814	In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells. Food and Chemical Toxicology, 2022, 159, 112722.	1.8	9
815	THC shows activity against cultured Plasmodium falciparum. Bioorganic and Medicinal Chemistry Letters, 2021, 54, 128442.	1.0	1
817	Cannabinoids for Symptom Management in Patients with Kidney Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 911-921.	2.2	4
818	Benefits, toxicity and current market of cannabidiol in edibles. Critical Reviews in Food Science and Nutrition, 2023, 63, 5800-5812.	5.4	8
819	An Optimized Terpene Profile for a New Medical Cannabis Oil. Pharmaceutics, 2022, 14, 298.	2.0	4
820	Cannabis for the Treatment of Attention Deficit Hyperactivity Disorder: A Report of 3 Cases. Medical Cannabis and Cannabinoids, 2022, 5, 1-6.	1.2	10
821	Chronic pain and medical cannabis: Narrative review and practice considerations in persons living with HIV. JACCP Journal of the American College of Clinical Pharmacy, 2022, 5, 342-353.	0.5	2
822	Evidence on the acute and residual neurocognitive effects of cannabis use in adolescents and adults: a systematic metaâ€review of metaâ€analyses. Addiction, 2022, 117, 1857-1870.	1.7	30

#	Article	IF	CITATIONS
823	Considerations for Cannabinoids in Perioperative Care by Anesthesiologists. Journal of Clinical Medicine, 2022, 11, 558.	1.0	7
824	A Phase I Trial to Determine the Pharmacokinetics, Psychotropic Effects, and Safety Profile of a Novel Nanoparticle-Based Cannabinoid Spray for Oromucosal Delivery. Medical Cannabis and Cannabinoids, 2022, 5, 9-19.	1.2	3
825	Medicinal cannabis pharmacokinetics and potential methods of delivery. Pharmaceutical Development and Technology, 2022, 27, 202-214.	1.1	6
826	Trends and characteristics of cannabis-associated emergency department visits in the United States, 2006–2018. Drug and Alcohol Dependence, 2022, 232, 109288.	1.6	17
829	Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review. Pharmaceuticals, 2022, 15, 210.	1.7	19
830	Understanding the Placental Biology of Tobacco Smoke, Nicotine, and Marijuana (THC) Exposures During Pregnancy. Clinical Obstetrics and Gynecology, 2022, 65, 347-359.	0.6	5
831	Animal Models Evaluating the Impact of Prenatal Exposure to Tobacco and Marijuana. Clinical Obstetrics and Gynecology, 2022, 65, 334-346.	0.6	1
832	Will the Pharmacologically Meaningful Halfâ€Life Please Stand Up?. Journal of Clinical Pharmacology, 2022, 62, 829-832.	1.0	1
833	Maternalâ€fetal transmission of deltaâ€9â€tetrahydrocannabinol (THC) and its metabolites following inhalation and injection exposure during pregnancy in rats. Journal of Neuroscience Research, 2022, 100, 713-730.	1.3	14
834	Developmental neurotoxicity of drugs of abuse. , 2022, , 359-377.		0
835	Zentrales Nervensystem. , 2022, , 301-510.		0
836	Applications of Cannabinoids in Neuropathic Pain : An updated review. Critical Reviews in Therapeutic Drug Carrier Systems, 2022, , .	1.2	0
838	Cannabis Legalization and Driving Under the Influence of Cannabis in a National Us Sample Revision 1. SSRN Electronic Journal, 0, , .	0.4	0
839	Cannabis-Based Oral Emulsion for Medical Purposes to Meet the Needs of Patients: Formulation, Quality and Stability. Pharmaceutics, 2022, 14, 513.	2.0	1
840	Cannabis, cannabidiol and tetrahydrocannabinol in sport: an overview. Internal Medicine Journal, 2022, 52, 1471-1477.	0.5	6
841	The Transdermal Delivery of Therapeutic Cannabinoids. Pharmaceutics, 2022, 14, 438.	2.0	21
842	Development of Stable Nano-Sized Transfersomes as a Rectal Colloid for Enhanced Delivery of Cannabidiol. Pharmaceutics, 2022, 14, 703.	2.0	29
843	Cyclobutanes in Smallâ€Molecule Drug Candidates. ChemMedChem, 2022, 17, .	1.6	59

#	Article	IF	CITATIONS
844	Development of a simulation-based experimental research framework for the characterization of cannabis-related driving impairment. Transportation Research Interdisciplinary Perspectives, 2022, 13, 100561.	1.6	1
845	Recent advances in electrochemical sensor technologies for THC detectionâ€"a narrative review. Journal of Cannabis Research, 2022, 4, 12.	1.5	9
846	Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study. Behavioural Neurology, 2022, 2022, 1-10.	1.1	4
847	Chronic Pain and the Endocannabinoid System: Smart Lipids – A Novel Therapeutic Option?. Medical Cannabis and Cannabinoids, 2022, 5, 61-75.	1.2	8
848	Effects of î"9-Tetrahydrocannibinol (THC) on Obesity at Different Stages of Life: A Literature Review. International Journal of Environmental Research and Public Health, 2022, 19, 3174.	1.2	9
849	Cannabis health survey on usage in women with spinal cord injury and knowledge among physicians: A cross-sectional study. Journal of Spinal Cord Medicine, 2023, 46, 291-297.	0.7	1
850	Guideline No. 425a: Cannabis Use Throughout Women's Lifespans – Part 1: Fertility, Contraception, Menopause, and Pelvic Pain. Journal of Obstetrics and Gynaecology Canada, 2022, 44, 407-419.e4.	0.3	4
851	Re: "Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial―by Crippa et al Cannabis and Cannabinoid Research, 2022, 7, 231-233.	1.5	2
852	Characterizing and Quantifying Extrahepatic Metabolism of $(\hat{a}^{\cdot})-\hat{l}^{\cdot}$ ⁹ -Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, $(\hat{A}\pm)-11$ -Hydroxy- \hat{l}^{\cdot} ⁹ -THC (11-OH-THC). Drug Metabolism and Disposition, 2022, 50, 734-740.	1.7	7
853	Directive clinique no 425a : Le cannabis aux différentes périodes de la vie des femmes— Partie 1 : Fertilité, contraception, ménopause et douleur pelvienne. Journal of Obstetrics and Gynaecology Canada, 2022, 44, 420-435.e4.	0.3	1
855	Environmental enrichment sex-dependently rescues memory impairment in FABP5 KO mice not mediated by brain-derived neurotrophic factor. Behavioural Brain Research, 2022, 425, 113814.	1.2	5
856	Medical marijuana for inflammatory bowel disease: the highs and lows. Scandinavian Journal of Gastroenterology, 2022, 57, 197-205.	0.6	1
857	Cannabidiol-Loaded Mixed Polymeric Micelles of Chitosan/Poly(Vinyl Alcohol) and Poly(Methyl) Tj ETQq0 0 0 rgB1	Qverlock	R 10 Tf 50 26
858	Pharmacokinetics and central accumulation of delta-9-tetrahydrocannabinol (THC) and its bioactive metabolites are influenced by route of administration and sex in rats. Scientific Reports, 2021, 11, 23990.	1.6	39
859	Drug-Drug Interaction Between Orally Administered Hydrocodone-Acetaminophen and Inhalation of Cannabis Smoke: A Case Report. Hospital Pharmacy, 0, , 001857872110613.	0.4	3
860	Strain-, Sex-, and Time-Dependent Antidepressant-like Effects of Cannabidiol. Pharmaceuticals, 2021, 14, 1269.	1.7	14
861	Medicinal Cannabis and Central Nervous System Disorders. Frontiers in Pharmacology, 2022, 13, 881810.	1.6	12
863	Cannabis use in patients with insomnia and sleep disorders: Retrospective chart review. Canadian Pharmacists Journal, 2022, 155, 175-180.	0.4	3

#	Article	IF	Citations
876	Sociodemographic and clinical profile of cannabis-induced psychosis: A comparative study. Industrial Psychiatry, 2021, 30, 132.	0.3	3
879	Cannabis for Medical Use: Versatile Plant Rather Than a Single Drug. Frontiers in Pharmacology, 2022, 13, 894960.	1.6	20
880	Effects of Cannabidiol on Locomotor Activity. Life, 2022, 12, 652.	1.1	8
881	Cannabinoids, Insomnia, and Other Sleep Disorders. Chest, 2022, 162, 452-465.	0.4	14
882	Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain). Current Rheumatology Reports, 2022, 24, 238-246.	2.1	9
883	The effects of acute Cannabis smoke or Δ9-THC injections on the trial-unique, nonmatching-to-location and five-choice serial reaction time tasks in male Long-Evans rats. Neurobiology of Learning and Memory, 2022, 192, 107624.	1.0	8
884	Advances of Drugs Electroanalysis Based on Direct Electrochemical Redox on Electrodes: A Review. Critical Reviews in Analytical Chemistry, 2024, 54, 269-314.	1.8	1
885	Cannabis for Medical Use: Analysis of Recent Clinical Trials in View of Current Legislation. Frontiers in Pharmacology, 2022, 13, .	1.6	8
886	Is There a Place for Medicinal Cannabis in Treating Patients with Sleep Disorders? What We Know so Far. Nature and Science of Sleep, 0, Volume 14, 957-968.	1.4	6
887	Chronic Cannabis Intoxication and Propofol-Induced Salivation: Causes and Considerations. Pathophysiology, 2022, 29, 223-232.	1.0	1
888	Cannabis abuse and dependence., 0,, 315-329.		0
889	Diagn \tilde{A}^3 stico, Manejo y Seguimiento de los Pacientes Intoxicados con derivados de Cannabis: una revisi \tilde{A}^3 n narrativa. , 2022, 7, 113-125.		0
890	Cannabis and Driving: Developing Guidelines for Safety Policies. Current Pharmaceutical Biotechnology, 2023, 24, 719-727.	0.9	2
891	Cannabis Use in Patients With Cancer: A Clinical Review. JCO Oncology Practice, 2022, 18, 743-749.	1.4	15
892	Branching out: redox strategies towards the synthesis of acyclic \hat{l} ±-tertiary ethers. Chemical Society Reviews, 2022, 51, 5878-5929.	18.7	7
893	A GPCR-based yeast biosensor for biomedical, biotechnological, and point-of-use cannabinoid determination. Nature Communications, 2022, 13, .	5.8	17
894	Pharmacokinetics of Cannabidiol Following Intranasal, Intrarectal, and Oral Administration in Healthy Dogs. Frontiers in Veterinary Science, 0, 9, .	0.9	17
895	Pharmacokinetics of Cannabis and Its Derivatives in Animals and Humans During Pregnancy and Breastfeeding. Frontiers in Pharmacology, 0, 13 , .	1.6	6

#	Article	IF	Citations
896	Strategies for enhancing the oral bioavailability of cannabinoids. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 313-322.	1.5	5
897	Cannabinoids and solid organ transplantation: Psychiatric perspectives and recommendations. Transplantation Reviews, 2022, 36, 100715.	1.2	4
900	The effects of subacute exposure to a water-soluble cannabinol compound in male mice. Journal of Cannabis Research, 2022, 4, .	1.5	2
901	Cannabisgebrauch bei Jugendlichen. Neuropsychiatrie, 0, , .	1.3	O
902	Pediatric Brain on Cannabinoids: Adverse Effects of Cannabinoid Products in Children and Adolescents. , 0, , .		0
903	Affinity Assays for Cannabinoids Detection: Are They Amenable to On-Site Screening?. Biosensors, 2022, 12, 608.	2.3	2
904	Assessing the influence of cannabis and alcohol use on different visual functions: A comparative study. Experimental Eye Research, 2022, 224, 109231.	1.2	2
905	Illegal drugs and periodontal conditions. Periodontology 2000, 2022, 90, 62-87.	6.3	5
907	Clinical Pharmacology of Cannabinoids. Psychiatry Update, 2022, , 13-26.	0.1	0
908	Neurodevelopmental Impact of Prenatal and Early Adolescent Cannabis Use and Resulting Neurocognitive Deficits., 2022,,.		0
909	Pharmacological Management of Neuropathic Pain., 2022,, 313-341.		0
910	Cannabis effects on the adolescent brain. , 2022, , 283-330.		0
911	Preliminary Evaluation of the Use of a Disposable Electrochemical Sensor for Selective Identification of \hat{l} "9-Tetrahydrocannabinol and Cannabidiol by Multivariate Analysis. SSRN Electronic Journal, 0, , .	0.4	0
912	Clinical Considerations for Cannabis in the Child and Adolescent Consultation-Liaison Setting. Psychiatry Update, 2022, , 81-90.	0.1	0
913	Driving under the Influence of Psychotropic Substances: A Technical Interpretation., 2022, 1, 7-15.		3
914	Glandular trichomes of medicinal plants: types, separation and purification, biological activities. Biologia Plantarum, 0, 66, 219-227.	1.9	2
915	Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial. Frontiers in Medicine, 0, 9, .	1.2	7
916	Systematic Review and Meta-analysis Seem to Indicate that Cannabinoids for Chronic Primary Pain Treatment Have Limited Benefit. Pain and Therapy, 2022, 11, 1341-1358.	1.5	2

#	Article	IF	Citations
917	Current Cannabidiol Safety: A Review. Current Drug Safety, 2023, 18, 465-473.	0.3	3
919	Increased identification of cannabis use among drivers involved in motor vehicle collisions using an expanded cannabis inventory. Academic Emergency Medicine, 2022, 29, 1301-1305.	0.8	1
920	Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimerâ \in TM s disease. Frontiers in Neuroscience, 0, 16, .	1.4	12
922	Cannabinoid Therapeutic Effects in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Biomedicines, 2022, 10, 2439.	1.4	4
923	Clinical Considerations for Cannabis Use and Cardiovascular Health. Medical Cannabis and Cannabinoids, 2022, 5, 120-127.	1.2	1
924	Emerging understanding of the effects of cannabis use during pregnancy. Birth Defects Research, 2023, 115, 129-132.	0.8	0
925	Marijuana and the Lung. Medical Clinics of North America, 2022, 106, 1093-1107.	1.1	5
926	Historical Pathways for Opioid Addiction, Withdrawal with Traditional and Alternative Treatment Options with Ketamine, Cannabinoids, and Noribogaine: A Narrative Review. Health Psychology Research, 2022, Vol. 10, .	0.6	4
927	Cannabis Intoxication, a Neglected Cause of Altered Level of Consciousness in Children: A Case Series. International Journal of Pediatrics and Child Health, 0, 9, 35-39.	0.1	0
928	Pediatric Considerations when Prescribing Cannabis. , 2022, , 143-153.		0
929	Long-Term Drug Use. , 2022, , 227-242.		0
930	Cannabis and Organ Damage: A Focus on Pancreatitis (to Include Different Scenarios). , 2022, , 1343-1352.		0
931	An Observational Cross-Sectional Survey Exploring the Indications for and Responses to Medical Marijuana Use in Certified Patients in Pennsylvania. Journal of Primary Care and Community Health, 2022, 13, 215013192211297.	1.0	6
932	Disguised Marijuana Edibles as a Public Health Concern in Pediatrics. Journal of Comprehensive Pediatrics, 2022, 13, .	0.1	0
933	"Flower Power― Controlled Inhalation of THC-Predominant Cannabis Flos Improves Health-Related Quality of Life and Symptoms of Chronic Pain and Anxiety in Eligible UK Patients. Biomedicines, 2022, 10, 2576.	1.4	6
934	The mystery behind the apprehensions of the selective cannabinoid receptor type-2 agonist BZO-HEXOXIZID (MDA-19) as a drug of abuse. Forensic Toxicology, 2023, 41, 142-150.	1.4	3
935	Pharmacokinetics of Cannabidiol in Sprague-Dawley Rats After Oral and Pulmonary Administration. Cannabis and Cannabinoid Research, 0, , .	1.5	5
936	Synthetic cannabinoid JWH-073 alters both acute behavior and in vivo/vitro electrophysiological responses in mice. Frontiers in Psychiatry, 0, 13 , .	1.3	2

#	Article	IF	CITATIONS
938	Preliminary evaluation of the use of a disposable electrochemical sensor for selective identification of \hat{l} "9-tetrahydrocannabinol and cannabidiol by multivariate analysis. Microchemical Journal, 2022, 183, 108108.	2.3	4
939	A new UHPLC-MS/MS method for cannabinoids determination in human plasma: A clinical tool for therapeutic drug monitoring. Biomedicine and Pharmacotherapy, 2022, 156, 113899.	2.5	4
940	Cannabinoids: Legal aspects, pharmacology, phytochemistry, probable targets from biological system, and therapeutic potential. Asian Journal of Pharmaceutical Research and Health Care, 2022, 14, 127.	0.0	0
941	Electrochemical biosensors based on saliva electrolytes for rapid detection and diagnosis. Journal of Materials Chemistry B, 2022, 11, 33-54.	2.9	7
942	Medical Cannabinoids as Treatment for Hypophosphatasia-Related Symptoms. Complementary Medicine Research, 0 , , .	0.5	1
943	Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?. F1000Research, 0, 8, 1394.	0.8	5
944	Cannabinoids and drug metabolizing enzymes: potential for drug-drug interactions and implications for drug safety and efficacy. Expert Review of Clinical Pharmacology, 2022, 15, 1443-1460.	1.3	8
945	Virtual screening and in vitro experiments highlight cannabidiol as a drugâ€ike phosphodiesterase 9 inhibitor. European Journal of Neuroscience, 2023, 57, 1954-1965.	1.2	6
946	Cannabinoid Exposure and Subjective Effects of THC and CBD in Edible Cannabis Products. Cannabis and Cannabinoid Research, 2024, 9, 320-334.	1.5	0
947	A Systematic Review of Medical Cannabinoids Dosing in Human. Clinical Therapeutics, 2022, 44, e39-e58.	1.1	4
948	Phytocannabinoids, the Endocannabinoid System and Male Reproduction. World Journal of Men?s Health, 2023, 41, 1.	1.7	3
949	An electrochemical aptasensor for l'"9-tetrahydrocannabinol detection in saliva on a microfluidic platform. Biosensors and Bioelectronics, 2023, 222, 114998.	5.3	6
950	Prolonged detection of cannabis in urine of a consumer in a Forensic hospital, Victoria, Australia, up to 102 days of abstinence - A case report., 2023, 2, 100089.		0
951	Effect of Cannabidiol Oil on Weight Loss in Diet-Induced Obese Mice: Validation Study. Journal of Korean Neuropsychiatric Association, 2022, 61, 281.	0.2	1
952	Should Per Se Limits Be Imposed For Cannabis? Equating Cannabinoid Blood Concentrations with Actual Driver Impairment: Practical Limitations and Concerns. Humboldt Journal of Social Relations, 2013, 1, 41-51.	0.3	1
953	The effects of cannabidiol on the driving performance of healthy adults: a pilot randomized clinical trial., 2022,, 100053.		1
954	Maternal and Fetal Exposure to (-)-l" ⁹ -tetrahydrocannabinol and Its Major Metabolites in Pregnant Mice Is Differentially Impacted by P-glycoprotein and Breast Cancer Resistance Protein. Drug Metabolism and Disposition, 2023, 51, 269-275.	1.7	3
955	Cannabis Use in Patients Seen in an Academic Radiation Oncology Department. Practical Radiation Oncology, 2023, 13, 112-121.	1.1	4

#	Article	IF	CITATIONS
956	Dysmenorrhoea: Can Medicinal Cannabis Bring New Hope for a Collective Group of Women Suffering in Pain, Globally?. International Journal of Molecular Sciences, 2022, 23, 16201.	1.8	1
957	Cannabidiol in urine is not a proof of CBD consumption—lesson learned from urine sample analysis in routine caseworks. Forensic Toxicology, 2023, 41, 213-220.	1.4	1
959	Approaches to Measuring Cannabis Use in Injury Research: Beyond Drug Detection. Current Epidemiology Reports, 0, , .	1.1	0
960	The Legalisation of Cannabis in South Africa. Advances in Business Strategy and Competitive Advantage Book Series, 2023, , 98-122.	0.2	1
961	Trends in emergency department visits associated with cannabis use among older adults in California, 2005–2019. Journal of the American Geriatrics Society, 2023, 71, 1267-1274.	1.3	4
962	Environmental toxins and neurodevelopment. , 2023, , 772-788.		0
963	The role of cannabinoids in pain modulation in companion animals. Frontiers in Veterinary Science, 0, 9, .	0.9	5
964	Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration. Pharmaceutical Research, 2023, 40, 1087-1114.	1.7	8
965	Cannabinoids to Fight Chemotherapy-Induced Adverse Effects. , 2023, , 1-28.		0
966	The effects of cannabidiol on subjective states, cognition, and psychomotor function in healthy adults: A randomized clinical trial. Fundamental and Clinical Pharmacology, 2023, 37, 663-672.	1.0	2
967	ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids. Regional Anesthesia and Pain Medicine, 2023, 48, 97-117.	1.1	22
968	Cannabinoids as a Potential Alternative to Opioids in the Management of Various Pain Subtypes: Benefits, Limitations, and Risks. Pain and Therapy, 2023, 12, 355-375.	1.5	5
969	Assessment of Delta-9-Tetrahydrocannabinol (THC) in Saliva and Blood After Oral Administration of Medical Cannabis With Respect to its Effect on Driving Abilities. Physiological Research, 0, , 703-712.	0.4	2
970	Therapeutic Benefits of Medical Cannabis. Physician Assistant Clinics, 2023, 8, 281-291.	0.1	0
971	Oral lipid-based formulations alter delivery of cannabidiol to different anatomical regions in the brain. International Journal of Pharmaceutics, 2023, 635, 122651.	2.6	4
972	Beyond Pain Relief: A Review on Cannabidiol Potential in Medical Therapies. Pharmaceuticals, 2023, 16, 155.	1.7	6
973	"Breaking bud― the effect of direct chemical modifications of phytocannabinoids on their bioavailability, physiological effects, and therapeutic potential. Organic and Biomolecular Chemistry, 2023, 21, 3715-3732.	1.5	4
974	Cannabinoids to Fight Chemotherapy-Induced Adverse Effects. , 2023, , 1-29.		0

#	ARTICLE	IF	CITATIONS
975	Cannabis Use Patterns and Whole-Blood Cannabinoid Profiles of Emergency Department Patients With Suspected Cannabinoid Hyperemesis Syndrome. Annals of Emergency Medicine, 2023, 82, 121-130.	0.3	1
976	Roadside screening tests for cannabis use: A systematic review. Heliyon, 2023, 9, e14630.	1.4	5
977	Establishment of a point of departure for CBD hepatotoxicity employing human HepaRG spheroids. Toxicology, 2023, 488, 153469.	2.0	0
978	Marijuana as medicine. , 2023, , 349-358.		0
979	Cannabis and Synthetic Cannabinoids. , 2016, , 147-164.		0
980	Analysis of Cannabinoids in Biological Specimens: An Update. International Journal of Environmental Research and Public Health, 2023, 20, 2312.	1.2	10
981	Nanoformulations as a strategy to overcome the delivery limitations of cannabinoids. Phytotherapy Research, 2023, 37, 1526-1538.	2.8	11
982	Measurement of \hat{l} "9THC and metabolites in the brain and peripheral tissues after intranasal instillation of a nanoformulation. Journal of Cannabis Research, 2023, 5, .	1.5	1
983	Delta-8-Tetrahydrocannabinol Exposure and Confirmation in Four Pediatric Patients. Journal of Medical Toxicology, 2023, 19, 190-195.	0.8	3
984	An update of nano-based drug delivery systems for cannabinoids: Biopharmaceutical aspects & therapeutic applications. International Journal of Pharmaceutics, 2023, 635, 122727.	2.6	8
985	Dedicated esophageal imaging may be unnecessary in marijuana-associated spontaneous pneumomediastinum: Findings from a retrospective cohort study. Frontiers in Surgery, 0, 10, .	0.6	0
986	Monitoring Perfusion Index in Patients Presenting to the Emergency Department Due to Drug Use. Journal of Personalized Medicine, 2023, 13, 372.	1.1	1
987	Place of therapeutic cannabis in France and safety data: A literature review. Annales Pharmaceutiques Francaises, 2023, , .	0.4	0
988	Therapieresistente Depressionen als Folge oder KomorbiditÃt von AbhÃngigkeitserkrankungen. , 2022, , 85-101.		0
989	Risk of Motor Vehicle Collisions and Culpability among Older Drivers Using Cannabis: A Meta-Analysis. Brain Sciences, 2023, 13, 421.	1.1	0
990	Limited Utility of Toxicology Testing at Delivery for Perinatal Cannabis Use. Hospital Pediatrics, 2023, 13, 317-325.	0.6	1
991	Evolving threat of pediatric ingestions: a discussion of cannabis and button batteries and their implications for children. Current Opinion in Pediatrics, 2023, 35, 316-323.	1.0	0
992	Pharmacokinetics of Orally Applied Cannabinoids and Medical Marijuana Extracts in Mouse Nervous Tissue and Plasma: Relevance for Pain Treatment. Pharmaceutics, 2023, 15, 853.	2.0	7

#	Article	IF	CITATIONS
994	Metabolic, toxicological, chemical, and commercial perspectives on esterification of dietary polyphenols: a review. Critical Reviews in Food Science and Nutrition, 0, , 1-40.	5.4	2
995	The effect of marijuana use on short-term outcomes with bariatric surgery. Surgery for Obesity and Related Diseases, 2023, 19, 964-970.	1.0	3
996	An Individuality of Response to Cannabinoids: Challenges in Safety and Efficacy of Cannabis Products. Molecules, 2023, 28, 2791.	1.7	6
997	Cannabinoids as Potential Cancer Therapeutics: The Concentration Conundrum. Cannabis and Cannabinoid Research, 0 , , .	1.5	1
998	A One Health perspective on comparative cannabidiol and cannabidiolic acid pharmacokinetics and biotransformation in humans and domestic animals. American Journal of Veterinary Research, 2023, , $1-9$.	0.3	3
999	Comparison of the influence of alcohol and cannabis on the dynamics of the accommodative response. Graefe's Archive for Clinical and Experimental Ophthalmology, 2023, 261, 2281-2289.	1.0	1
1000	Modulation of pulmonary immune function by inhaled cannabis products and consequences for lung disease. Respiratory Research, 2023, 24, .	1.4	5
1001	Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment. Cancers, 2023, 15, 2119.	1.7	5
1003	Cannabis Pharmacogenomics: A Path to Personalized Medicine. Current Issues in Molecular Biology, 2023, 45, 3479-3514.	1.0	2
1004	î" ⁹ -THC and CBD in Plasma, Oral Fluid, Exhaled Breath, and Urine from 23 Patients Administered Sativex. Cannabis and Cannabinoid Research, 0, , .	1.5	0
1014	Age-related considerations in the use of cannabinoids: Focus on drug interactions, physiology, and drug effects., 2023,, 355-363.		0
1015	Synthetic cannabinoid receptor agonists compared to î"9-tetrahydrocannabinol: Neurological effects and beyond., 2023,, 487-496.		0
1023	Acute and chronic impact of cannabis on human cognition. , 2023, , 139-153.		0
1024	The impact of prenatal cannabis exposure: An overview. , 2023, , 55-69.		0
1030	On the feasibility of a portable electrochemical measuring system for the on-site measurement of cannabinoids. , 2023, , .		1
1055	Indischer Hanf, syn. 'Cannabisâ€~ (Cannabis sativa var. indica). , 2023, , 557-564.		0
1080	Effect of recreational cannabis use on bone mineral density: a systematic review. Osteoporosis International, 2024, 35, 391-399.	1.3	0
1081	Substanzbezogene Störungen. , 2023, , 709-759.		0

#	Article	IF	CITATIONS
1083	Prenatal Exposure to Cannabis: Effects on Childhood Obesity and Cardiometabolic Health. Current Obesity Reports, 2024, 13, 154-166.	3.5	0
1095	Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent., 2023,, 203-222.		0